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Abstract
The transcriptome is the entire set of transcripts that are expressed from the genes of an organism under
some conditions and at a particular time. The transcriptome can be sequenced into reads in order to find
clues about genes and protein sequences, structures, and their functions. While in the past, transcriptome
sequencing technology used to be costly and slow, more recently, next generation sequencing technology
has emerged, decreasing the cost and increasing the speed of genome, transcriptome and exome sequencing.
However, raw sequences come with artifacts, and hence preprocessing the reads is required for downstream
analysis. In this dissertation, we have proven that preprocessing sequencing data is required for better
performance throughout the genomics processing.
In addition, we propose many machine learning models that serve as contributions to solve a biological problem. First, we present Zseq, a linear time method that identifies the most informative genomic
sequences and reduces the number of biased sequences, sequence duplications, and ambiguous nucleotides.
Zseq finds the complexity of the sequences by counting the number of unique k-mers in each sequence as
its corresponding score and also takes into the account other factors, such as ambiguous nucleotides or high
GC-content percentage in k-mers. Based on a z-score threshold, Zseq sweeps through the sequences again
and filters those with a z-score less than the user-defined threshold. Zseq is able to provide a better mapping
rate; it reduces the number of ambiguous bases significantly in comparison with other methods. Evaluation
of the filtered reads has been conducted by aligning the reads and assembling the transcripts using the reference genome as well as de novo assembly. The assembled transcripts show a better discriminative ability
to separate cancer and normal samples in comparison with another state-of-the-art method.
Studying the abundance of select mRNA species throughout prostate cancer progression may provide
some insight into the molecular mechanisms that advance the disease. In the second contribution of this
dissertation, we reveal that the combination of proper clustering, distance function and Index validation
for clusters are suitable in identifying outlier transcripts, which show different trending than the majority
of the transcripts, the trending of the transcript is the abundance throughout different stages of prostate
cancer. We compare this model with standard hierarchical time-series clustering method based on Euclidean
distance.
Using time-series profile hierarchical clustering methods, we identified stage-specific mRNA species
termed outlier transcripts that exhibit unique trending patterns as compared to most other transcripts
during disease progression. This method is able to identify those outliers rather than finding patterns among
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the trending transcripts compared to the hierarchical clustering method based on Euclidean distance. A
wet-lab experiment on a biomarker (CAM2G gene) confirmed the result of the computational model. Genes
related to these outlier transcripts were found to be strongly associated with cancer, and in particular,
prostate cancer. Further investigation of these outlier transcripts in prostate cancer may identify them as
potential stage-specific biomarkers that can predict the progression of the disease.
Breast cancer, on the other hand, is a widespread type of cancer in females and accounts for a lot of
cancer cases and deaths in the world. Identifying the subtype of breast cancer plays a crucial role in selecting
the best treatment. In the third contribution, we propose an optimized hierarchical classification model that
is used to predict the breast cancer subtype. Suitable filter feature selection methods and new hybrid feature
selection methods are utilized to find discriminative genes. Our proposed model achieves 100% accuracy for
predicting the breast cancer subtypes using the same or even fewer genes.
Studying breast cancer survivability among different patients who received various treatments may help
understand the relationship between the survivability and treatment therapy based on gene expression. In
the fourth contribution, we have built a classifier system that predicts whether a given breast cancer patient
who underwent some form of treatment, which is either hormone therapy, radiotherapy, or surgery will
survive beyond five years after the treatment therapy. Our classifier is a tree-based hierarchical approach
that partitions breast cancer patients based on survivability classes; each node in the tree is associated with
a treatment therapy and finds a predictive subset of genes that can best predict whether a given patient
will survive after that particular treatment. We applied our tree-based method to a gene expression dataset
that consists of 347 treated breast cancer patients and identified potential biomarker subsets with prediction
accuracies ranging from 80.9% to 100%. We have further investigated the roles of many biomarkers through
the literature.
Studying gene expression through various time intervals of breast cancer survival may provide insights
into the recovery of the patients. Discovery of gene indicators can be a crucial step in predicting survivability
and handling of breast cancer patients. In the fifth contribution, we propose a hierarchical clustering method
to separate dissimilar groups of genes in time-series data as outliers. These isolated outliers, genes that trend
differently from other genes, can serve as potential biomarkers of breast cancer survivability.
In the last contribution, we introduce a method that uses machine learning techniques to identify transcripts that correlate with prostate cancer development and progression. We have isolated transcripts that
have the potential to serve as prognostic indicators and may have significant value in guiding treatment
decisions. Our study also supports PTGFR, NREP, scaRNA22, DOCK9, FLVCR2, IK2F3, USP13, and
CLASP1 as potential biomarkers to predict prostate cancer progression, especially between stage II and
subsequent stages of the disease.
viii
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Chapter 1

Introduction
1.1

Transcriptome

Molecular biology is a branch of biochemistry that studies the molecular basis of biological
activity among biomolecules in a cell, such as the synthesis of DNA to RNA, and then to
proteins, as well as the regulatory mechanisms of the products of the genes. DNA is the
material that holds heredity information. Stored in the nucleus of the cell, it is arranged
into regions called chromosomes, which carry the genes. Each gene consists of a long chain
of nucleotides which is designated to perform a specific function. Roughly speaking, a gene
transcribes into mRNA, which then translates into protein. Nonetheless, some parts of the
gene “splice out” – called introns, while the remaining parts –coding parts or exons– “splice
into” messenger RNA, out of which a portion is translated into protein. Transcription and
translation are one-way direction processes as depicted in Figure 1.1; they form what is known
as the central dogma of molecular biology. Based on the fact that different transcripts for
specific genes may lead to a different protein, we decided to analyze the gene expression and
quantification on both gene level as in Chapter 4, and more detailed on the transcription
level as in Chapters 2, 3, and 5.
The transcriptome or usually known as all RNAs is the repertoire of all DNA molecules
that transcribe into RNA and the events that are associated with the transcription process. Unlike the genome, which is usually fixed except for DNA mutations, variations or
1
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Figure 1.1: Central dogma of molecular biology.

alterations, transcriptome analysis opens the door for studying a number of external factors involved in gene expression such as environmental conditions, regulatory proteins, gene
transport, and others. The transcriptome includes the gene transcript expression profiling
and alternative splicing activity. It comprehensively includes the overall messenger RNA
(mRNA) expression in one cell, which is also known as single-cell transcriptome. Alternative
splicing is a regulated process during gene expression that results in coding multiple variants
or isoforms of RNA, which are then tranlated into different proteins via open reading frames
(ORFs). In this process, particular exons of a gene may be included within or excluded from
the final transcript (processed mRNA produced from that gene) [1]. Figure 1.2 depicts two
different scenarios of transcriptions of the same gene to form two different proteins.

1.2

Cancer

Cancer is a very complex disease that can be defined as unusual growth of cells. The
defining feature of this disease is the rapid creation of abnormal cells that grow beyond
their usual boundaries. According to the World Health Organization (WHO), cancer is the
second leading cause of death world-wide [2]. Cancer starts by transforming healthy cells
into tumor cells in a multistage process that generally progresses from a pre-cancerous lesion
to a metastatic tumor. These changes are the result of the interaction between a person’s
2
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Figure 1.2: Alternative splicing allows a gene to transcribe into two or more different ways using different
combinations of exons to produce different proteins.

genetic factors and three categories of external agents, including but not limited to:
• physical carcinogens agents, such as ultraviolet and ionizing radiation.
• chemical carcinogens agents, such as asbestos, components of tobacco smoke, aflatoxin
(a food contaminant), and arsenic (a drinking water contaminant).
• biological carcinogens agents, such as infections from certain viruses, bacteria, or parasites [2].
Similarly, the staging cancer system was devised by Pierre Denoix to notate the different stages of cancer while progression takes place [4]. This notation system is known as
Classification of Malignant Tumors (TNM), where:
• T describes the size of the primary tumor and whether it has invaded nearby tissue.
• N describes regional lymph nodes that are involved.

3

Figure 1.3: TNM stages of prostate cancer. Courtesy: Comprehensive Urology [5].

• M describes distant metastasis, namely, how cancer spreads from one organ of the body
to another distant organ.
In Chapter 3, we present an approach that is used to quantify transcript reads over TNM
classification to interpolate the progression for prostate cancer tumours. More details about
the stages and the sub-stages of the samples are included in that chapter. Figure 1.3 depicts
the normal and different TNM stages of prostate tissues.
Prostate is a gland in the male reproductive system, and prostate cancer is the development of cancerous cells in the prostate. While the majority of prostate cancers metastasize
very slowly, some metastasize very fast [6]. The aggressiveness of prostate cancer can be
measured using Gleason score. Gleason score is a grading system which was introduced by
Dr. Donald Gleason to classify the cancer in the prostate tissue based upon its microscopic
4

Figure 1.4: Gleason score patterns which was drawn by Dr. Gleason Courtesy: [3].

appearance. The pathologist can determine the score based on collecting several details such
as tumor’s shape, tumor size, and which prostate tissue the tumor exists. The higher score
indicates greater risks and higher mortality. Cell morphology determines the structure, the
size, and how the shape of cells looks like such as cocci, bacilli, spiral shapes. The cancer
can be dominant or non dominant cell morphology in specific tissue based on whether or
not the majority of cells are cancer. The pathologist grade the dominant cell morphology
from 1 to 5 , and another score from 1 to 5 for the non dominant cell morphology. The total
addition of the two score form the total Gleason score that ranges from 2 to 10. Figure 1.4
depicts the Gleason scale patterns that pathologist can use to determine the score for both
dominant and non-dominant cell morphology.
Gleason score (pattern) descriptions are the following:
• Gleason pattern 1: is the most well-differentiated tumor pattern. It is a well-defined
nodule of single/separate, closely/densely packed, back-to-back gland pattern that does
not spread into adjacent healthy prostatic tissue. The glands are round or might be oval
5

shaped and proportionally large, when comparing them to those of Gleason pattern 3
tumors.
• Gleason 2: is fairly well circumscribed nodule of single, separate glands. However, the
glands are looser in arrangement and not as uniform as in pattern 1. Minimal invasion
by neoplastic glands into the surrounding healthy prostate tissue may be seen. Similar
to Gleason 1, the glands are usually larger than those of Gleason 3 patterns, and are
round to oval in shape. Thus the main difference between Gleason 1 and 2 is the density
of packing of the glands seen and invasion is possible in Gleason 2, not in Gleason 1 by
definition.
• Gleason pattern 3: is a clearly infiltrative neoplasm, with extension into adjacent
healthy prostate tissue. The glands vary in size and shape and are often long/angular.
They are usually small to medium size/micro-glandular in comparison to Gleason 1-2
grades. The small glands of Gleason 3, in comparison to the small and poorly defined
glands of pattern 4, are distinct glandular units.
• Gleason pattern 4: glands are no longer single/separated glands similar to those seen
in patterns 1-3. They look fused together, difficult to distinguish, with rare lumen
formation compared to Gleason 1-3 which usually all have open lumens (spaces) within
the glands, or they can be cribriform-(denoting an anatomical structure that is pierced
by numerous small holes. Resembling the cribriform plate/similar to a sieve. An item
with many perforations). Fused glands are chains, nests, or groups of glands that are
no longer entirely separated by stroma. Fused glands contain occasional stroma giving
the appearance of partial separation of the glands.
• Gleason pattern 5: Neoplasms have no glandular differentiation (thus not resembling
normal prostate tissue at all). It contains sheets (groups of cells almost planar in
appearance (similar to the top of a box), solid cords, or individual cells [7].
Gleason scores are often grouped based on similar behavior: Grade 2-4 being welldifferentiated neoplasm, Grade 5-6 intermediate-grade neoplasm, Grade 7 moderately 6

poorly differentiated grade neoplasm, and Grade 8-10 high-grade neoplasm. We have developed a machine learning approaches to obtain markers for prostate cancer Gleason score
[8]and laterality (location in the tissue) [9].
On the other hand, breast cancer is the most common type of cancer in female population
worldwide [2]. Breast cancer can be classified using the TNM classification and molecular
subtypes. In Chapter 4, we present an approach used to analyze the gene expression of
breast cancer patients to find markers that are related to specific subtypes using supervised
machine learning methods.
The tumor tissue under the microscope suggest nonlinear structure which is known as
tumor heterogeneity. Heterogeneity may show distinct morphological and phenotypic profiles, including cellular morphology, gene expression, proliferation, metabolism, motility, and
metastatic potential. Tumor heterogeneity has been observed in many type of cancer, breast
and prostate cancers are not any exception [16]. Targeting heterogeneity for furthur analysis can be in experimental and computational side, single cell sequencing and bulk tumor
sequencing can be both applied in the coputational side; In the first, an indicual cell can
be entirely sequenced amd the mutational profiles for distict cells can be analyzed with no
ambguity. However, this method is lacking of sufficient number of cells to obtain statistical significance. While in the bulk tumor sequencing, identifying rare mutations is difficult
because of the low frequency in the (bulk) mixture of cells.
Perou and colleagues categorized the molecular subtypes of breast cancer based on the
relative expression of 500 differentially expressed genes [17, 18], the five intrinsic categories
including:
• Luminal A breast cancer is hormone-receptor-positive (estrogen-receptor and/or progesteronereceptor positive), HER2 negative.
• Luminal B breast cancer is hormone-receptor-positive (estrogen-receptor and/or progesteronereceptor positive), and either HER2 positive or HER2 negative with high levels of Ki-67.
• Triple-negative/basal-like breast cancer is hormone-receptor-negative (estrogen-receptor
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and progesterone-receptor negative) and HER2 negative.
• HER2-enriched breast cancer is hormone-receptor-negative (estrogen-receptor and progesteronereceptor negative) and HER2 positive.
• Normal-like breast cancer is similar to luminal A, but is hormone-receptor positive
(estrogen-receptor and/or progesterone-receptor positive), and HER2 negative.
A recent research has introduced 10 molecular subtypes of Breast Cancer [10]. The aim of
this new subtype categorization is to obtain more separation in the largest subgroup of breast
cancer. In the 70% of breast cancers that are classified as estrogen-receptor positive/HER2negative in Luminal A, there is a tremendous heterogeneity; some groups of those patients
have different prognosis than others [13]. The genomic variation at a specific locus can lead
to a different expression for that gene. Curtis et al. generated a map of CNAs, CNVs,
and SNP for the new breast cancer classes. The integrative 10 classes which are named
InClust 1-10 have different clinical outcomes. Figure 1.5 shows the number of patients in
each InClust followed by the number of death from the specific disease between brackets
from the study [10].

1.3

Microarray

Chang et al introduced the microarray as anti-body microarray in 1983 [11]. In 1995, Schena
et al. used the microarray to monitor the expression of genes in parallel by reading complementary DNAs on glass using high-speed printing robotics [12]. After that, the microarray
industry established itself as the most used technology for reading gene expression with many
different industrial leaders in the market such as Affymetrix, Agilent, Applied Microarrays,
Arrayjet, Illumina, and others.
Microarray is capable to read the expressions of thousands of genes at the same time. a
microscope slides which known as DNA chips are positions to measure the gene expression
at the mRNA level that is known as transcriptome. Two mRNA samples, one from normal
tissue ( healthy) that is called reference sample and the other one from the cancer or some
8

Figure 1.5: The new breast cancer 10 subtypes clinical courtesy: [10], Kaplan–Meier plot of 15-years breast
cancer survival for each InClust.

other disease, are converted into complementary DNA (cDNA). if a gene from both samples
have a similar expression, the corresponding chip will appear as yellow, if the experiment
gene has expressed less than the reference gene, the correspondence chip will appear as red,
and if it is expresses more, the corresponding chip will appear as green.
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1.4

Next-generation sequencing

Next generation sequencing (NGS) technology allows us to sequence the molecular events
fast at a very low cost, as well as higher sample throughput. The applications of NGS in
transcriptome analysis are commonly known as RNA Sequencing or RNA-Seq. There are
two main methods used to reconstruct the gene transcripts from sequenced reads. The first
one consists of comparing the reads to the reference genome for the same organism or a
similar known organism, while the second one consists of reconstructing the transcription
data from the reads without comparing it to known reference genome, which is known as de
novo assembly. Both techniques have been used in this thesis – see Chapter 2.

1.5

Machine learning

Machine learning is a branch of computer science that uses mathematical, statistical, and
logical techniques to make the machine learn from data without being programmed. In 1959,
Arthur Samuel came up with the name machine learning by combining artificial intelligence
in gaming and pattern recognition algorithms to make the machine learn from previous
experience. Data-driven predictions or decisions are the main purpose of machine learning.
Ever since, machine learning has evolved to include more applications and more challenges
to overcome by the machine including:
• Supervised learning, which means making the machine learn from labeled samples to
build the ability to predict or classify new unlabeled samples. Supervised learning
mainly includes classification and regression. We used these techniques in Chapters 2,
4, and 5.
• Unsupervised learning, in which the samples are not labeled, and hence, the machine
will attempt to group the samples based on similarities among them. Clustering is the
most popular application of unsupervised learning. In Chapter 3, we have contributed
to this area of learning by proposing a hierarchical clustering model that identifies
10

outliers from time-series transcriptomic profiles. We further enhanced this algorithm
by extending the proposed method – see Chapter 4.
• Semi-supervised learning: since labeling samples is an expensive process, it starts with
labeling small number of samples, and then use the rest of the unlabeled samples in the
learning (training phase) which is more economically feasible. Mixing the unsupervised
techniques on the unlabeled data with the supervised techniques on both labeled and
unlabeled samples is a common technique in industry. The conjunction of labeled and
unlabeled samples may improve the accuracy of the learning system [14].
• Feature selection and extraction techniques are used to select or extract the most informative features (attributes) of the data that are relevant to the classification problem
that we are trying to solve. This includes feature selection (such as filter, wrapper, and
hybrid techniques), feature extraction, and dimensionality reduction techniques.
• Artificial neural network (ANN) and deep learning: In the attempt to mimic human
biological neural learning process, computer scientists created learning algorithms based
on connected nodes that can learn by forward propagation from the input layer to the
output layer going through the hidden layer. The nodes in the hidden layers have a
learning functions which is also known as activation functions. The nodes are connected
using weighted edges, which can be updated in the network back propagation phase to
reduce the error of the learning.
• Deep learning: A deeper neural networks or a neural network with multiple hidden layers
which recently emerge due to the revolutionary development in computer resources, such
as graphic processing units (GPU), and tensor processing unit (TPU). The complicated
deeper network are becoming more practical to optimize the machine learning; unlike
the ealier version of ANN, deep learning is about building multi-hidden layers of learning
rather than trying to understand the way that human brain works, which is known as
neuroscience technology [15].
• Time-series: Series of data that are generated from the same function or source in
11

time order. Time series applications exist in our daily life, including financial stocks,
weather forecast, heart beat rate, speech, and others. In scientific domains, time series
applications almost exist in all fields such as signal processing, earthquake prediction
and astronomy.

1.6

RNA-Seq preprocessing

NGS technology generates a large number of reads (short sequences), which contain a vast
amount of genomic data. The sequencing process, however, comes with artifacts such as
biased sequences, sequence duplications, and ambiguous nucleotides. Preprocessing of the
sequences is mandatory for further downstream analysis. In Chapter 2, we present Zseq,
a linear time method that identifies the most informative genomic sequences and de-rank
the sequences with artifacts. The complexity of a word in any language is that have nonrepetitive terms, so the word cat has a high complexity and most likely to be a word, while
cacacaca has a low complexity and most likely not to be a word in English language. In
order to measure the complexity of RNA sequences, Zseq calculates the complexity of the
sequences by counting the number of unique k-mers in each sequence as its corresponding
score and also takes into the account other factors such as ambiguous nucleotides or high
GC-content percentage in k-mers. Based on a z-score threshold, Zseq sweeps through the
sequences again and filters those with a z-score less than the user-defined threshold.
The Zseq algorithm is able to provide a better mapping rate; it reduces the number of
ambiguous bases significantly in comparison with other methods. Evaluation of the filtered
reads has been conducted by aligning the reads and assembling the transcripts using the
reference genome as well as de novo assembly. The assembled transcripts show a better
discriminative ability to separate cancer and normal samples in comparison with another
state-of-the-art method in Chapter 2. Moreover, de novo assembled transcripts from the
reads filtered by Zseq have longer genomic sequences than other tested methods. Estimating
the threshold of the cutoff point is introduced using labeling rules with very optimistic
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results.

1.7

Outlier detection from time-series cancer RNA-Seq data

Studying the abundance of selected mRNA species throughout prostate cancer progression
may provide insight into the molecular mechanisms that advance the disease. In Chapter 3,
we reveal that the combination of proper clustering, distance function and index validation
for clusters are suitable in identifying outlier transcripts, which exhibit different trends than
the majority of the transcripts. Unlike an earlier works in which we clustered the profiles
to find patterns as illustrated in Appendix A, this work focuses on finding the trend of
a transcript is the abundance throughout different stages of prostate cancer. In modeling
cancer progression, the stages are represented as time points, and the increase in transcript
abundance throughout those time points are cubic-spline interpolated. After profiling the
transcripts, we universally aligned the profile to a coordinate profile z [47], then we hierarchically clustered the profiles to find outliers profiles that have large distances and differently
trend than the other profiles.
Using a hierarchical clustering method for time-series profile data, we identified stagespecific mRNA species termed outlier transcripts that exhibit unique trending patterns as
compared to most other transcripts during disease progression. This method is able to
identify those outliers rather than finding patterns among the trending transcripts compared
to the hierarchical clustering method that is based on the Euclidean distance. Our proposed
algorithm was able to identify the outliers and cluster them in singleton-clusters or in clusters
containing a small number of transcripts, while the hierarchical clustering based on Euclidean
distance was trying to find patterns rather than exclude the outliers.
A wet-lab experiment on a marker gene CAMK2G confirmed the results of the computational model on a dataset of samples from a Chinese population. Genes related to
these outlier transcripts were found to be strongly associated with cancer, and in particular,
with prostate cancer. Further investigation of these outlier transcripts in prostate cancer
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may identify them as potential stage-specific indicators that can predict disease progression,
leading to novel drugs or therapies.
Studying gene expression through various time intervals of breast cancer survivability may
provide deeper insight into the recovery of the patients. Gene expression values are different
in various stages of progression of the disease. Discovery of gene biomarkers can be a crucial
step in predicting survivability and handling breast cancer patients. In Chapter 4, we present
an approach used to enhance a hierarchical clustering method to separate dissimilar groups
of genes in time-series data as outliers. These isolated outliers (genes that trend differently
from other genes) can serve as potential markers of breast cancer survivability. Noise is
undesirable case or unwanted case in data distribution, the noise can be generated randomly
or non-randomly. Outliers are cases who are removed from the main body of the data, where
the proximities of the outlier to the other cases are generaly small, in another words, the
measurment of the outlier is away from the mean of the other measurements in the same
class [21]. In supervised learning, the outlier can be determined by identifying the border of
the class using support vector machines [21] or anti-Bayesian [22]; this technique known as
one class classification.
Outliers can be studied to analyse unusual situation since the outlier can be a legitimate
case, while it is usually treated as noise or error in a measurment. It also may introduce
novelty in any distribution. Since cancer is unusual growth of the cells, unusual growth of
the cancerous cells over time needs to be carefully studied to analyze the nature of cancer,
in addition to the motives of the expression at some certain time points.
We partition the time axis (time points) into bins of length six months starting from 1-6
up to 55 months intervals and, for each gene, we average its expression level over all patients
who appear in a survival bin. Gene expressions throughout those time points are cubic
spline interpolated to create a trending profile for each gene. First, we universally align the
gene expression profiles to minimize the total area between them. Then, we cluster them
using a sliding window approach and hierarchical clustering based on minimum squared error
distances.
14

To the best of our knowledge, this work is the first time-series model that is built on the
survival time of patients after the treatment. With this approach, we identified 60 genes
(including 36 oncogenes and 18 tumor suppressor genes) as potential biomarkers of breast
cancer survivability.
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Chapter 2

Zseq : an approach for preprocessing
next generation sequencing data
2.1

Introduction

A low-complexity sequence of nucleotides has highly biased distribution of nucleotides in a
way that makes the sequence less diverse of unique k-mers of nucleotides. The lower the
complexity of a sequence, the more likely that the sequence will be mapped to different parts
of the genome. In other words, when we process low-complex sequences, there is less chance
that we can align it to a specific part of the genome uniquely. This low level of certainty
regarding the real position of a sequence, makes it less desirable to be used.
Poly A/Poly T is a chain of A or T, used to prime the three and five sites in a genome
sequence during cDNA library preparation [6]. Poly A/T sequences may cause bias in the
reads. The intronic Poly A/T tails tend to splice out rather than staying between coding
exons [7]. The GC content represents the ratio of a G-C pair in the genome sequence. The
stop codons show a significantly high ratio of A-T nucleotides [8], while coding codons have
a higher GC content [9]. The GC content of a gene plays an important role in carrying
the genetic information. The GC content of the human genome varies among different
chromosomes. However, the average GC content of the human genome is 41% [10]. The
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representation of A+T sequences can be significantly lower, because in the preparation of a
standard library a gel slice is used and heated up to 50 ◦ C, thereby increasing the bias of the
GC content [11].
Fastqc can be used to check the quality of the sequenced reads that is coming from high
throughput sequencing pipelines. It provides a modular set of analyses wether your data
should be preprocessed and which kind of biases or artifacts which the raw data may have
at each base pair position in the reads [12]. Fastqc can works FASTA and FASTQ format
where both are similar except that FASTQ provides a quality measurment of each sequenced
base pair. Fastqc is useful to view the content of the data before and after preprocessing the
sequences using tools such as Zseq.
There are different techniques that try to remove those sequences with low-complexity
patterns from samples. Morgulis et al. presented the symmetric DUST method [13], which
masks low-complexity regions in a sequence to overcome context sensitivity in calculating
the complexity score. Schmieder et al. proposed two methods to evaluate the sequence
complexity [14]. The first method is based on entropy as a measure. The second method,
which is a variant of the DUST algorithm based on BLAST search, filters out the lowcomplexity score sequences. Both methods consider each triplet of nucleotides as a word.
One of the downsides of the previous methods is that they focus only on the complexity
of the sequences. This can be misleading in some cases due to the highly biased nature
of the sequences. In this chapter, we propose a novel method called Zseq, which decreases
the uniqueness score of highly biased regions, thereby filtering highly biased sequences and
low-complexity sequences.
2.1.1

Methods

Figure 2.1 depicts the process of finding reads with improved quality. Each module is explained in detail in the next few paragraphs.
In the first step, Zseq scans all the reads and calculates the uniqueness score for all reads.
The uniqueness score corresponding to each read is equal to the number of unique k-mers in
20

Figure 2.1: Schematic representation of the process for filtering reads using the Zseq method.

that read. Zseq considers the default k-mer size, w, as 4-mers, which makes the vocabulary of
four nucleotides (A,T,C,G) to be 44 = 256 words. As the long reads may contain thousands
of nucleotides, the 3-mer size is not sufficient to measure the complexity of the reads. This
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Figure 2.2: Distribution of the normalized uniqueness scores for all reads in sample (SRR202054) (µ =
25.8169, σ = 7.1681).

is because a 3-mer word can exist many times in the same read without being considered as
unique, even when it is associated with different nucleotides each time. Zseq excludes the
5-mers of the low-complex/biased artifacts, such as ambiguous bases (N), PolyA/T and GC
content, from being unique by decreasing the unique score of the reads by one for each 2w
in order to reduce the chances of selecting this sequence later. The uniqueness score of each
read is then normalized by dividing it by the length of the read. The normalized uniqueness
scores of all reads are stored in a vector with the same order of the read in the input file.
Figure 2.2 shows the distribution of the normalized uniqueness scores for all reads for sample
SRR202054 from the prostate cancer data set used in the study of [16]. The x-axis shows
the normalized uniqueness scores, while the y-axis shows the number of reads. As shown in
the figure, the penalized sequences have a very small score down to -30. These are sequences
that have been generated using reads that contain long PolyA/T sequences, very high GC
content, or very high number of ambiguous nucleotides (N).
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In the next step, Zseq calculates the mean and standard deviation for the normalized
uniqueness scores. The mean of the normalized uniqueness scores of all reads is calculated
in the first loop. The variance is also calculated linearly using a Naı̈ve algorithm to reduce
the cost of this step. The standard deviation is calculated from the variance of the vector of
the normalized uniqueness scores.
Next, for each normalized uniqueness score, we calculate the z-score using the mean, µ,
and the standard deviation, σ, as follows:

z = (s − µ)/σ.

(2.1)

The z-score represents how many standard deviations the normalized uniqueness score of
the read is away from the mean µ for all normalized uniqueness scores. In other words, if
a read has a z-score of 0, it means that the read has the normalized uniqueness score of µ,
while a z-score of value 1 means that the normalized uniqueness score is away exactly one
standard deviation from the µ. Figure 2.3 shows the z-scores for all reads in the sample
(SRR202054), where the x-axis is the z-score of the normalized uniqueness scores, while the
y-axis indicates how many reads a particular z-score has in the sample.
Finally, the user-adjustable threshold θ is used to determine whether or not to select the
reads, if the z-score of the normalized uniqueness score of the reads is greater than or equal
to θ, the read will be selected; otherwise, it will be filtered out.
2.1.2

Estimating the cuttoff point

A data driven method based on the labeling rules is used to filter out the reads with low
uniqueness score. The method automatically finds the cutoff point c to compensate θ in the
histogram of reads’ uniqueness scores and removes those reads whose uniqueness score is less
than c. The labeling rules model calculates the first quartile q1 and third quartile q3 using
the mean and the standard deviation which both are in the first loop through the reads. The
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Figure 2.3: Distribution of the z-scores of the normalized uniqueness scores corresponding to each read for
sample (SRR202054).
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cut-off point is calculated as follows:
c = q1 − g(q3 − q1)

(2.2)

where g is the g-factor that can be calculated as follows:
g = (h − q1)/h

(2.3)

with h being the highest value in the histogram of reads’ uniqueness scores. After calculating
the cut-off point c, the method sweeps again throughout the reads and selects those that
have uniqueness score ≤ c

2.2

Results

In our experiments, we used the prostate cancer data set utilized in the study of [16]. The
data set is publicly available in NCBI Gene Expression Omnibus (GEO) under accession no.
GSE29155. It contains 11 samples in total, where seven of them belong to tumor tissues
and the remaining four samples are benign. We measured the GC content and the number
of ambiguous bases of the outcomes of each method, and then aligned the results of both
methods to the human genome using Tophat2 as the alignment method [18].
DUST takes a value that ranges from 0 and 100 as the complexity threshold, while Zseq
takes a z-score value as a complexity threshold, which shows how many standard deviations
the normalized uniqueness score of the read is away from the mean. For the DUST method
we chose the value 5 as the threshold, which means that the value of the complexity of the
read has to be greater than or equal to 5 to be selected; otherwise, DUST will ignore the
read. For Zseq, we have chosen -1.5 as the value of the threshold, which makes the read
good to be selected if the z-score of that read is greater than or equal to -1.5. The reason
behind selecting these two thresholds is that both methods filter almost the same number of
reads in each sample.
The filtered reads using Zseq have less GC content than the filtered reads using DUST. It
25

Figure 2.4: Percentage of GC content for all filtered reads using the Zseq histogram (a) with µ = 52.63%
and σ = 12.08%.

Figure 2.5: Percentage of GC content for all filtered reads using the DUST histogram with µ = 53.09% and
σ = 12.36%.

also has smaller standard deviation which makes the reads centered more around the mean
than DUST. Figure 2.4 and Figure 2.5show the GC content distributions for both methods
applied on the same sample set (SRR202058).
Zseq shows a slight improvement in reducing the GC content, mapping rate and mapping
time, while dropping the number of ambiguous bases drastically in comparison with DUST.
Table 2.1 shows that the number of ambiguous bases, N, in the filtered reads using Zseq have
drastically decreased compared with the ambiguous bases that have been filtered out using
DUST in all samples. For example, the number of occurrences of N in sample SRR202054
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for filtered reads by DUST is 19,177, while there are only 11,135 filtered reads using Zseq for
the same sample. The results indicate that Zseq slightly shrunk the GC content percentage
distribution and reduced the mean of the GC content percentage. For sample SRR202055,
the mean of the GC content is 52.48 ± 12.10% using Zseq, which is less than 52.91 ± 12.38%
obtained using DUST. Zseq also shows better mapping alignment for the filtered reads than
DUST for most of the samples. For example, in sample SRR202061, the reads filtered by
Zseq have 79.20% mapping rate, which is greater than 77.90% mapping rate for reads filtered
by DUST, the only exception is sample SRR202062, which shows a similar mapping rate of
71.30% for both DUST and Zseq.
Table 2.1: Comparison of the results of applying Zseq on samples from the prostate cancer data set as a
result of applying DUST on the same samples.
Sample Number
SRR202054
SRR202055
SRR202056
SRR202057
SRR202058
SRR202059
SRR202060
SRR202061
SRR202062

2.2.1

Occurrences of N
40,690
42,965
40,243
42,630
16,643
17,741
19,958
2,156
5,837

Original
Mean GC content
52.82 ± 14.06%
53.01 ± 13.74%
52.94 ± 13.99%
52.94 ± 13.94%
53.12 ± 14.03%
52.56 ± 13.88%
53.44 ± 13.98%
50.06 ± 11.50%
52.81 ± 13.64%

Mapping rate
91.50%
91.20%
91.40%
91.30%
91.00%
90.70%
90.90%
77.00%
69.10%

Occurrences of N
11,135
9,336
10,721
10,403
14,023
14,042
13,775
1,849
5,122

Zseq
Mean GC content
52.61 ± 12.20%
52.48 ± 12.10%
52.67 ± 12.22%
52.65 ± 12.22%
52.63 ± 12.08%
52.18 ± 12.02%
53.23 ± 12.09%
48.87 ± 9.96%
52.69 ± 11.77%

Mapping rate
93.00%
92.40%
92.80%
92.60%
92.40%
92.00%
92.40%
79.20%
71.30%

Occurrences of N
19,177
19,470
18,336
20,018
16,198
17,091
17,281
2,100
5,466

DUST
Mean GC content
52.89 ± 12.33%
52.91 ± 12.38%
52.95 ± 12.36%
52.93 ± 12.36%
53.09 ± 12.36%
52.61 ± 12.28%
53.51 ± 12.21%
49.95 ± 11.12%
52.91 ± 11.84%

Mapping rate
92.80%
92.10%
92.60%
92.40%
92.30%
91.90%
92.30%
77.90%
71.30%

De novo sequences validation

Using Trinity de novo assembler [19], transcripts have been reconstructed for the original
reads of sample SRR202058, reads that have been filtered by DUST and reads that have been
filtered by Zseq. In the next step, all three sets of constructed transcripts were evaluated by
searching the assembled transcripts with the human genome sequences using BLAST [20].
The set of the reconstructed transcript using the filtered reads by Zseq contains a higher
number of long sequences in comparison with the other two sets. Figure 2.6, 2.7, and 2.8
show the meaningful sequences for each set. Some of the sequences, which were built using
the reads filtered by Zseq, have a length of 1000 bp or more along with high alignment score;
while the sequence length is slightly more than 300 bp using the reads filtered by DUST and
200 bp for the original reads without filtering.
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Figure 2.6: Biologically meaningful human genomic sequences found using BLAST. De novo assembled
transcripts using original reads.

Figure 2.7: Biologically meaningful human genomic sequences found using BLAST. De novo assembled
transcripts using reads filtered by DUST.

2.2.2

Machine learning validation

In another experiment, we used an independent data set that contains 12 samples (six tumor
and six matched normal) [10]. Using these samples, three data sets were generated, one from
the original reads, one by applying DUST on the reads, and the third one by applying Zseq
on the reads for all samples. In the next step, all reads corresponding to each data set have
been aligned to human genome hg19 using Tophat2 [18] and Cufflinks assembler [22] with
default parameters to assemble the transcripts to the human genome and estimate their
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Figure 2.8: Biologically meaningful human genomic sequences found using BLAST. De novo assembled
transcripts using reads filtered by Zseq.

abundance, which is measured by FPKM value (fragments per kilo bases of exons for per
million mapped reads). Table 2.2 shows the the average mapping rate of reads filtered by
each method. Each generated data set using filtered reads has 43,497 features (transcripts)
Table 2.2: Average mapping rate of transcripts using the data set generated by the original reads, reads
filtered by DUST and reads filtered by Zseq.
Original
88.90%

DUST
90.10%

Z-seq
90.40%

with FPKM values. Also, each of the 12 samples was labeled by cancer or matched benign.
The FPKM value equals 0 if the transcript has not been found to be present in that sample.
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We measured the number of transcripts that can individually separate all cancer samples
from normal samples perfectly, with 100% accuracy. In other words, we want to compute
the number of transcripts generated using filtered reads by each method, in such a way that
the FPKM values corresponding to cancer samples can be separated from of those FPKM
of normal samples. Figure 2.9 depicts two transcripts; transcript a has clearly separable
FPKM values, while in transcript b, the FPKM values cannot be separated accurately.

Figure 2.9: An example of two transcripts, one with separable FPKM values (a), and another transcript
with inseparable FPKM values (b).

Table 2.3 shows the number of transcripts that contain separable FPKM values. These
results indicate that applying Zseq influences the alignment tool and assembler to quantify
more meaningful transcripts that can discriminate cancer and normal samples in comparison
with the DUST method and original reads.
Table 2.3: the number of discriminative transcripts for each of the three data sets.
Data set
Original
Filtered by Dust
Filtered by Zseq

n of discriminative transcripts
167
159
231

Moreover, using Chi2 statistical test [6] on the 231 discriminative transcripts from the Zseq
data set, the NM 001145410 transcript corresponding to NONO gene was the most significant
transcript among all other transcripts in all three data sets. NONO is known to regulate in
different types of cancer such as breast and prostate cancer [24, 25]. Next, a support vector
machine (SVM) with linear kernel (SVM-L) was applied on the three data sets using this
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Table 2.4: Some artifacts measurements of prostate cancer samples which were preprocessed by EC-Zseq.
EC-Zseq
Sample
Occurrences
Mean
GC Mapping
Number
of N
content
Rate
52.71
±
SRR202054
33,124
93.40%
13.40%
52.91
±
SRR202055
27,890
93.30%
12.76%
52.82
±
SRR202056
34,453
93.50%
13.07%
52.68
±
SRR202057
30,321
93.40%
12.52%
52.87
±
SRR202058
14,760
92.90%
13.43%
52.18
±
SRR202059
15,203
92.80%
12.62%
53.31
±
SRR202060
16,704
92.70%
12.09%
49.11
±
SRR202061
1,926
79.70%
10.62%
532.70
±
SRR202062
5,484
72.10%
12.47%

transcript as feature. SVM is a supervised learning machine that tries to find an optimal
separating hyperplane between classes [26]. Using a leave-two-out cross-validation scheme,
the classification returns 100% accuracy for the Zseq data set, 91.66% for the DUST data
set, while it was down to 83.33% in the original reads data set.
2.2.3

Result for estimated cutoff point Zseq

The results of the estimated cutoff point Zseq as shown in Table 2.4 and Table 2.5 suggested
that the method does not find the optimal point. The result of Zseq on the prostate cancer
data set using the threshold θ = -1.5 in prevouis section out performed the result of the
EC-Zseq. Despite having better mapping rate, EC-Zseq falls short in mean GC content to
Zseq with θ, in number of ambiguous nucleotides compared to DUST and Zseq with θ, and
in number of decisive transcript compared to Zseq with θ. However, EC-Zseq still shows
better results than the original data set or pre-processing the data set using DUST method.
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Table 2.5: the number of decisive transcripts for the data set that was pre-processed by EC-Zseq.
Data set
pre-processed by EC-Zseq

2.3

n of Decisive transcripts
222

Conclusion

We have presented a novel method for filtering the reads that reduces the number of biased,
duplicate or ambiguous sequences. Our method finds the complexity of the sequences by
assigning a unique score to each read. Using a user-defined threshold, the user can filter
the reads with a score less than the threshold. Applying the proposed method on real
samples shows that the Zseq algorithm is statistically sound and provides a better mapping
rate, while it significantly reduces the number of ambiguous bases in comparison with other
state-of-the-art methods. Estimating the cutoff point using labeling rules shows a good
result. The Zseq method is publicly available and can be accessed using the following link:
http://sourceforge.net/projects/zseq/.

32

Bibliography
[1] Sebastian M Waszak, Helena Kilpinen, Andreas R Gschwind, Andrea Orioli, Sunil K
Raghav, Robert M Witwicki, Eugenia Migliavacca, Alisa Yurovsky, Tuuli Lappalainen,
Nouria Hernandez, et al. Identification and removal of low-complexity sites in allelespecific analysis of chip-seq data. Bioinformatics, 30(2):165–171, 2014.
[2] Enrico Lavezzo, Luisa Barzon, Stefano Toppo, and Giorgio Palù. Third generation
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Chapter 3

Identifying biomarkers of prostate
cancer progression using transcript
outliers from time-series clusters
3.1

Background

Clustering time-series methods have been used in bioinformatics mainly for gene expression
profiles [1, 2]. Rueda et al. proposed a clustering method that, first, aligns the gene expression profiles together to minimize the total areas between the gene profiles, and then
clusters the profiles using an agglomerative clustering method based on the furthest neighbor
distance between each pair of clusters [3]. Also, they used a modified version of the I-index
cluster validity function [4] to validate the optimum number of clusters. Subhani et al. proposed a cubic spline interpolation for gene expression profiles, then clustering gene profiles
using k-means clustering with multiple alignment input (k-MCMA) and expectation maximization clustering with multiple alignment (EMMA), and compared it with the variation
co-expression detection (VCD) method [5]. Different cluster validity indices have been used
in this work including Davies-Bouldin’s (DB) index [6]. Each time-series clustering method
uses a distance function to define the similarity between samples as well as between clusters.
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Different biological clustering models need different distance functions and the difference
between the best distance function and the others can be substantial [7]. Distance functions
can be divided into metric and non-metric methods.
Euclidean distance is one of the most common used distance to find the dissimilarity
between gene expression profiles [8,9]. Vedell et al. [8] used the hybrid dynamic dendrogram
cutting method, from the R/dynamicTree Cut package, to obtain transcript abundance profiles. The samples from rats liver were hierarchically clustered based on Euclidean distance.
Gene expression changes were identified by reverse transcriptase polymerase chain reaction
in rat livers which was treated with Targret in for three-time points 2, 7, and 21 days. These
showed similar gene expression changes at all three-time points, arguing some steady-state
effect. Different patterns of gene expression allowed one to predict certain physiologic consequences of agonist treatment. Ferrari et al. [9] proposed a clustering method by using
meta-learning systems. They introduce a new problem characterization mechanism and two
ranking combination schemes. From the clustering problems, the method extracts three sets
of meta-attributes; the first uses the problems’ attributes as traditional direct characterization method, the second method applies an indirect method based on the Euclidean distance
between objects, and the third one combines the first two methods. Euclidean distance and
other correlation measurements require normalization.
Chiu et al. [2] interpolated gene expression using cubic B-splines interpolation to estimate
the missing values in the time-series, utilizing sliding-window, affinity propagation, gene
relativity graph and a consensus process to cluster the time-series gene expression models.
Chira et al. [10] proposed a shape-output clustering method that analyzes time series data
to study co-expressed gene growth patterns. The changes in the RNA abundance levels have
been used to cluster genes based on their shape measured over time in several samples. It has
been shown that there is a relationship between production variables and gene expressions .
Natural cubic spline interpolation is a spline interpolation method to approximate a function from discrete points. Cubic spline interpolation can correlate the data points efficiently
and effectively [11]. Previous works have primarily focused on clustering similar gene expres38

sion profiles. Usually, the developmental growth of a process through time is polynomial. To
the best of our knowledge, our study is the first to assume that cancer stages are time points
to approximate disease progression. The assumption stems from the fact that any biological
function is a continuous process and prostate cancer progression is not any exception. Most
of studies apply clustering to detect outliers. Pamula et al. proposed k-means clustering to
capture outliers [12], while Marghny et al. used a genetic k-means model that focuses on
detecting outliers and removing them since they serves as noise [13].
In this work, outlier transcripts are selected because they trend in a different way than
other transcripts and hence may serve as a biological indicator of change. We provide some
biological insight into the transcripts isolated and discuss the potential use of this information
for biological insight into cancer progression. This may provide biological insight into the
relationship between the abnormal expression of outlier transcripts and cancer progression.

3.2

Materials and methods

RNA-seq data generated from prostate cancer patient tumor samples spanning the spectrum of stage/sub-stages of disease progression was preprocessed and changes in transcript
abundance over time assessed using cubic spline interpolation. After universally aligning
transcript profiles, they were clustered using an agglomerative clustering approach based
on the area between the profiles as distance measure. For the wet lab experiment, the
cell culture is MNU series of prostate cancer cell lines (WPE1-NA22, WPE1-NB14, WPE1NB11, WPE1-NB26), which mimic stages in prostatic intra-epithelial neoplasia (PIN) and
progression to invasive cancer. Cells were cultured using complete keratinocyte serum free
(KSF) medium supplemented with epidermal growth factor and bovine pituitary extract
(Invitrogen). QRT-PCR. Total RNA was extracted using the Qiagen RNeasy Kit as per
manufactures instructions. RNA was subjected to cDNA synthesis using Quanta qScript
cDNA SuperMix. Quantitative PCRs were performed using the Fast SYBR-Green master mix (Thermo Fisher). To calculate relative gene expression, GAPDH mRNA was am-
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Table 3.1: Tumor samples that are analyzed from the first dataset.
Stage/Sub-stage
T1cN0M0
T2aN0M0
T2bN0M0
T2cN0M0
T3bN0M0
T4N0M0

Samples
ERR031038
ERR031032
ERR031026
ERR299297
ERR031044
ERR299295
ERR031040
ERR299298

plified as an internal control. The following primer sequences were designed for GAPDH
(5’-GCACCGTCAAGGCTGAGAAC-3’ and 5’-GGATCTCGCTCCTGGAAGATG-3’) and
CAMK2G (5’-GGGACCTGAAGCCTGAGAAC-3’ and 5’-GGAGCCCTTGATCCCATCTG3’).
3.2.1

Data pre-processing

The first dataset contains samples from the Chinese population. Using eight of 28 paired
samples (matched tumor and adjacent normal) in a data set from NCBI-SRA:ERP000550,
we preprocessed each sample using Zseq [14] and then aligning its mRNA reads to the human
reference genome hg19. We then constructed a database of all expressed transcripts. Figure 3.1 depicts the preprocessing pipeline starting with aligning the reads corresponding to
each sample using Tophat2, which is a splicing junction mapper that utilizes the short read
alignment Bowtie. The accepted hits of the aligned reads are used to construct the gene
transcripts for Homo sapiens using Cufflinks [16] which assembles the transcripts guided
by the transcript annotation and estimates the abundance of each transcript. The second
dataset from NCBI-SRA:GSE54460 contains 106 samples from the North American population [17]. We processed the samples using Zseq [14], then aligned the reads and constructed
the transcripts using STAR [17] and RSEM [19].
Table 3.1 shows the list of samples used in this work. The stage of each sample is indicated
in the number following T, and sub-stage as a lower case letter following the number (ex.
T1c refers to stage 1 and sub-stage c). All the samples used in this study have no lymph
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RNA-Seq Samples

Aligning Reads
Accepted Hits

Reconstructing Transcripts
Assembeled
Transcripts

Figure 3.1: Preprocessing pipeline for each sample in the data set.

node involvement and are non-metastatic (indicated by N0M0). Each sample in Table 3.1
had to go through the pre-processing pipeline to assemble the transcripts of that sample’s
mRNA reads.
By tracking changes in the relative abundance of transcripts with a common transcription
start site, we identified changes in splicing for each stage/sub-stage. We found differentially
expressed transcripts in correlation with various prostate cancer stages/sub-stages by estimating abundance of transcripts corresponding to each of these stages. For this, we used
Cuffdiff, which is a utility included in the Cufflinks package that uses accepted hits from the
aligned reads from each stage/sub-stage alongside the merge of all assembled transcripts,
and then uses statistical approaches to determine the differentially expressed genes and
transcripts in each of the cancer stages/sub-stages.
In the next step, a time-series data set was created from differentially expressed transcripts
throughout prostate cancer stages/sub-stages. The features of this data set are stage/sub-
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stages which are explained in Table 3.2. The abundance of the transcript at each stage/substage measured by Fragments Per Kilobase of transcript per Million mapped reads FPKM,
while the samples are the transcripts that have at least one significant FPKM value at one
of the stages/sub-stages. Totally, 19,698 transcript profiles have been extracted, where each
profile represents a sample in the proposed time-series model. The log of each FPKM values
of the profiles at all stages was calculated to reflect the fold change of the transcript expression
throughout different stages/sub-stages. The final data set contains the log(FPKM) value for
each feature for all profiles.
Table 3.2: Staging and description of the prostate cancer patent cohort [18].
Prostate
Description
stage

3.2.2

T1c

The tumour is not detectable via
imaging techniques. Cancer is detected using a needle biopsy performed due to an elevated serum
PSA.

T2a

The tumour is in half, or less than
half, of one of the prostate glands
two lobes.

T2b

The tumour is in more than half of
one lobe, but is not in both lobes.

T2c

The tumour is in both lobes but confined within the prostatic capsule.

T3b

The tumour has invaded one or both
of the seminal vesicles.

T4

The tumour rises to other organs

Natural cubic spline interpolation

Subhani et al. [5] reformulated the natural cubic spline interpolations of the time-series
profiles using arbitrary functions that are continuously integrable on a finite interval [5]. In
this work, we have utilized the reformulated cubic spline method to interpolate all profiles to
represent the transcript profile through prostate cancer progression. For profile x(t), where
t is a vector that represent time points [t1 , t2 , ..., tn ], x(t) is interpolated continuously as:
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x1 (t)
if t1 < t < t2 ,




x(t) = xj (t)
if tj−1 < tj < tj+1 ,





x (t) if t
n−1
n−1 < t < tn .

(3.1)

xj (t) = xj3 (t − tj)3 + xj2 (t − tj)2 + xj1 (t − tj)1 + xj0 .(t − tj)

(3.2)

where

xj (t) interpolates x(t) in interval [tj , tj+1 ], with spline coefficients xjk ∈ R, for 1 ≤ j ≤
n − 1 and 0 ≤ k ≤ 3, the interpolated x(t) spline has the natural condition,which means the
first and second derivatives of the spline at each interval xj (t) equals to zero.
Figure 3.2-a) shows the interpolated profiles for all 19,698 extracted transcripts profiles.
3.2.3

Universal alignment

Given data set X={x1 (t), x2 (t), ..xm (t} where m is the number of profiles. Cubic spline
interpolated profiles were universally aligned by shifting the interpolated transcript profiles
in such away that the integrated squared error between any two of those profiles is minimal.
Subhani et al. enhanced the pairwise alignment for all possible pair of profiles by aligning
all profiles into one particular profile z(t) = 0 (universal alignment), then proving both
approaches will achieve the same results. Figure3.2-b) shows the universal alignment for all
profiles.
3.2.4

Distance function

Based on the pairwise alignment between two profiles x(t) and y(t) , the distance between
them after aligning, vertical shifting, y(t) to x(t) is the area a between the two curves in
such way that a is the minimum square error; in other words, shifting y(t) to obtain the
minimum possible area between the two curves.
Z

tn

[x(t) − y(t)]dt

amin =
0
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(3.3)
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Figure 3.2: The 19,698 interpolated transcript profiles, each profile consists of the log(FPKM) values of the
transcripts expressions throughout prostate cancer stages/sub-stages(a), the profiles after universal alignment(b).

All profiles are aligned to the profile z(t)in such a way that distance between each profile
and z(t) is minimized; then, the distance matrix D between all profiles is calculated based
on the result of equation 3.3 between each possible pair from all profiles.
Profile clustering
The idea of detecting outliers using one of the clustering methods is to single out the profile
that is less similar to the other profiles. Then we place it in either a cluster of one profile, or a cluster with a very small number of profiles with similar trend. To achieve this
goal, an agglomerative clustering method has been implemented to hierarchically cluster the
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profiles based on the maximum dissimilarity with the other profiles in a new cluster. The
agglomerative clustering method start from the number of profiles as the number of clusters,
in which each cluster contains one profile, and then continues merging the nearest clusters.
The distance between two clusters C1 and C2 determined by the distance between the furthest profiles v and w where profile v ∈ C1 while w ∈ C2; the constructed D matrix is used
to determine the distance between v and w. The merging process between clusters continues
repeatedly until it reaches the desired number of clusters k.
3.2.5

Determining the desired number of clusters

The desired number of cluster k is determined using Profile Alignment and Agglomerative
Clustering (PAAC) index. PAAC index is an upgraded version of I-index by Rueda et al.
to solve the problem of penalizing the index value for the large number of clusters in the
I-index [3]. Visualizing the clusters’ profiles for each different number of cluster k, and the
visual representations of PAAC values for different k helps to select the best k.
PAAC was applied on both the proposed method and the hierarchical clustering method
based on Euclidean distance. For the proposed method, the PAAC values chart as shown in
Figure 3.3 shows that the PAAC value peaks when k = 31 and then start declining with no
sign of improvement for k > 31. While the PAAC values for the latter method suggests that
PAAC value peaks when k = 8 and start steadily declining for k > 8 as shown in Figure 3.4,
we kept measuring it up to k = 31 to check whether or not the value of PAAC may match
for both methods when k = 31.

3.3

Results and discussions

The method was implemented using Matlab, applied on the outcome data set from the
preprocessing pipeline. The agglomerative clustering showed a discriminative ability towards
outliers. The desired number of clusters was carefully chosen using validity indices as well
as visual observation of the clusters. Using validity indices for a different number of clusters,
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Figure 3.3: PAAC values for the proposed method for the first data set.
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Figure 3.4: PAAC values for the hierarchical clustering based on Euclidean distance for the first data set.

PAAC suggested 31 as the optimum number of clusters for p = 2 and q=0.7, where q
is the coefficient of normalizing the number of clusters increment and p the coefficient of
the degree of the index. Cluster 2, which includes the majority of the transcripts (19,656
profiles, to be exact), is the background cluster as shown in Figure 3.7, where the rest of the
clusters are those that contain the outliers profiles as shown in Figures 3.9 and 3.10. The
hierarchical clustering based on the Euclidean distance clustered the profiles into 8 clusters
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Figure 3.5: PAAC values for the proposed method for the second data set.
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Figure 3.6: PAAC values for the hierarchical clustering based on Euclidean distance for the second data set.

based on the suggestion of PAAC analysis, which was addressed earlier. Despite having less
number of clusters than the proposed method, the main cluster of the hierarchical method
has less number of profiles (18,784) compared to the proposed method, and the main cluster
of hierarchical missing many of the transcripts on the main trend as shown in Figure 3.8,
while the proposed method’s main cluster has a trimmed-looking profiles, where the outlier
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Figure 3.7: The first dataset: cluster 2 - main cluster for the proposed method.
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Figure 3.8: The first dataset: cluster 2 - main cluster for the hierarchical clustering based on Euclidean
distance method.

transcripts are removed.
3.3.1

Biological prioritization of transcripts

There is no overlapped transcripts between the pulled out list from the two dataset. The
two datasets are taking from different populations, where the first one was sampled from
Chinese populations while the second one was sampled from North American populations.
There are many differences from the genomic side between the two populations. For both
datasets, some of the genes corresponding to outlier transcripts are shown to be involved in
prostate cancer. Tables 3.3, 3.4 show these genes, their corresponding detected transcripts,
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Figure 3.9: The first dataset: clusters 1 to 16 of 31 distinct clusters detected by our proposed model.

and the cluster number shown in Figures 3.9 and 3.10. Some other genes are involved in
other types of cancers were also detected as outliers.
The STMN1 gene codes for Stathmin 1, an intracellular phosphoprotein that is upregu49

Figure 3.10: The first dataset: clusters 17 to 31 of 31 distinct clusters detected by our proposed model.

lated in most epithelial cancers, including prostate cancer. Increased expression levels are
correlated with poor prognosis and disease progression. STMN1 phosphorylation is required
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Figure 3.11: The second dataset: clusters 1 to 12 of 20 distinct clusters detected by our proposed model.

for microtubule assembly during mitosis and constitutive phosphorylation may cause oncogenesis. Decreased levels of STMN1 leads to epithelial-mesenchymal transition and metastasis
through p38 and TGF-B mechanisms. As a result, it has been suggested that the expression
levels of STMN1 may be stage dependent [20].
The gene product of calcium/calmodulin dependent protein kinase II gamma (CAMK2G)
is one of four subunits belonging to the multifunctional serine/threonine protein kinase family. CAMK2G has been shown to be an enhancer of cell growth and survival in many
cancers including leukemia, lung cancer and liver cancer [21–23] (1-3). CAMK2G is also
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Figure 3.12: The second dataset: clusters 12 to 20 of 20 distinct clusters detected by our proposed model.

known to interact with many tumourigenic signalling pathways such as β-catenin, NF-κB
and Stat3 [21, 23]
Runt-Related Transcription Factor 3 (RUNX3) gene product is frequently downregulated
in prostate cancer [24]. Decreased levels of RUNX3 lead to increased vascular endothelial
growth factor (VEGF) secretion and thereby increased angiogenesis. RUNX3 downregulation
also plays a role in both tumorigenesis and metastasis through dysregulation of TIMP-

Table 3.3: Genes and transcripts that correspond to prostate cancer were clustered as outliers for the first
dataset.
Gene

Transcripts

STMN1
CAMK2G
RUNX3
MSMB
PLA2G2A

NM
NM
NM
NM
NM

005563
001222
004350
002443
001161728
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Cluster
number
29
19
22
31
8

Table 3.4: Genes and transcripts that correspond to prostate cancer were clustered as outliers for the second
dataset.
Gene

Transcripts

FAM27L
DMKN
ACSM3
NUDT19
ACP1
POLR2A

NR 028336
NR 033746
NM 005622
NM 001105570
NR 024080
NM 000937

Cluster
number
1
5
8
11
12
18

2/MMP-2 levels [24].
The microseminoprotein beta (MSMB) gene encodes prostate secretory protein 94, a
member of the immunoglobulin binding factor family. It is synthesized by the epithelial cells
of the prostate gland and secreted into the seminal plasma. It has been shown that the
expression of this gene is decreased in prostate cancer [25, 26]. Its mechanism as a tumor
suppressor is unclear, but may involve suppressing cell growth and fungicidal activity [27].
The PLA2G2A gene codes for the Phospholipase A2 group 2A extracellular enzyme that
plays a role in both tumorigenesis and the inflammatory response [28]. PLA2G2A has
been shown to be upregulated in prostate cancer and is associated with, a poor response to
chemotherapy as well as an overall poor prognosis. It has been suggested that the PLA2G2A
enzyme might suppress genes that are induced by interferons [29], and is a downstream target
of the HER/HER2 pathway [28].
DMKN gene in the second dataset cluster 6 was associated with prostate cancer in earlier
studies [30, 31]. Srivastava et al. sequenced whole genome of 28 samples, and they identified
65 gene mutations present with higher confidence in at least one of the 14 prostate tumors
analyzed, DMKN was one of them. Out of 186 genes were found to be downregulated by
miR-138-5p. Gao et al. identified 5 potential targets including DMKN, EIF4EBP1, NINJ1,
PER1 and ST6GALNAC4 in prostate cancer cell [31]. Many of the genes related to the
transcripts identified from the second dataset were already proven to be linked to certain
cancers. Rotunno et al. finding suggests the use of APC1 gene expression’s from peripheral
whole blood (PWB) can be used as a marker of stage I Lung Adenocarcinoma [32]. Ruan et
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al. findings indicate that ACSM3 is a novel prognostic marker and a potential therapeutic
target for hepatocellular carcinoma(HCC) [33]. Sayagues et al. suggest that disruption of
the FAM27L gene may play a role in the malignant transformation and/or the metastasis
of collateral tumors into the liver [34]. Wang et al. detailed that the nudix hydroxylase
(NUDT) family of genes may have notable roles in cancer growth and metastasis. Their
study determined the prognostic ability of NUDT genes in clear cell renal cell carcinoma
(ccRCC) [35]. Yoo et al. findings suggest that POLR2A can influence prognosis in earlystage of non-small cell lung cancer (NSCLC) patients [36].
Biological validation of CAMKG2

Using the MNU cell line series that mimic early through late stages of progression we isolated
mRNA and studied the relative transcript abundance of CAMK2G using qRT-PCR. We
determined that the biological data achieved a trend that mimicked what was predicted in
our computational model as Figure 3.13. In the second dataset N M1 72171 transcript for
CAMK2G is trending as seen in Figure 3.14. Overall trending of this CAMK2G transcript
which is extracted from the North American dataset is different from the CAMK2G outlier
transcript which is extracted from the Chinese dataset. However, the trending is dropping
down in the latest stage is similar is similar for both of them, and also similar to the one
pulled from the wet-lab experiment.

Conclusions
This work introduces a time-series model of interpolating transcripts expression values
throughout cancer stages. A prostate cancer data set from Chinese population were preprocessed to form time-series profiles that contain the expression values at each stage. Those
profiles were clustered by an agglomerative clustering method based on area between the
profiles as a distance. The method was able to discriminate the outliers who trend different than the other profiles. Related genes with those outliers transcripts were found to be
strongly related to cancer in general, and prostate cancer in particular.
54

Relative mRNA Expression
CAMK2G

*
*

6
5
4
3
2
1
0
-1

NB26
NB14
NB11
Prostate Cancer Progression

NA22

Figure 3.13: Comparison of CAMK2G mRNA expression in prostate cancer cells mimicking prostate cancer
progression. QRT-PCR was performed to determine relative mRNA expression of CAMK2G in the MNU
series of prostate cancer cell lines that mimic early through to late stages of progression (NA22, stage 1 ;
NB14, stage 2; NB11, stage 3; and NB26, stage 4). ∗p < 0.05, n = 3.
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Figure 3.14: CAMK2G - N M1 72171 transcript in the second dataset.

A wet lab experiment was conducted on camk2g gene which was identified as an outlier
in the first dataset, it mimicked what was predicted in our computational model. Further
wet lab experiments on identified markers is the next step to explore the biological functions
of these markers throughout different prostate cancer stages. Some of these markers may be
valuable in predicting disease progression, and may represent a novel therapeutic target in
preventing or treating advanced stages of the disease.
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Chapter 4

Machine learning approaches for
breast cancer data analysis
In this chapter, we propose three models to analyze breast cancer outcomes: a supervised
model to find indicators for breast cancer subtypes and two methods to analyze breast cancer
survivability –where the first model is supervised while the other one is unsupervised model.
The unsupervised model is the extension of our proposed method presented in Chapter 3.

4.1

Supervised Hierarchical model to Analyze Breast Cancer Data

Breast cancer is a widespread cancer type in females and accounts for many cancer cases
and cancer deaths in the world. Identifying the type of breast cancer increases the chances
of survivability. In this section, two hierarchical models are proposed, where the first one
is used to predict the breast cancer subtype, and the second is to find marker genes that
guide the treatment type throughout survivability. Suitable filter feature selection methods
and new hybrid feature selection techniques are utilized in our models to find discriminative
genes.

62

4.1.1

Hierarchical supervised model for predicting breast cancer subtypes

Predicting the breast cancer subtypes is a multi-class classification problem. Machine learning methods have been used for predicting breast cancer subtypes [1], [2], [3].
In [3], Rezaeian et al. proposed a new hierarchical model to predict breast cancer subtypes.
They used Chi-square feature selection method to find informative genes in their model,
which consists of four steps. In each step, one subtype is predicted. In the first step, Basal is
predicted versus Her2, LumA, LumB, and Normal. The dataset is divided into two classes,
one for Basal and another class for the remaining three subtypes and Normal. Chi-square
feature selection is applied to find a suitable subset of genes for predicting Basal against
the remaining four classes. Then the SVM-L classifier is utilized for identifying the type of
instances. If an instance is not classified as Basal, the sample goes to the second step. In
the second step, Normal instances are classified versus Her2, LumA, and LumB in the same
way. Her2 subtype is identified against LumA and LumB subtypes in the third step. Finally,
LumA subtype is separated from LumB.
4.1.2

Methods

The framework of the proposed model consists of four steps. In each step, one subtype is
predicted. Each step consists of two phases: feature selection and classification. In the first
phase, a discriminative subset of genes is selected based on the subtype which is going to
be predicted in that step. In the second phase, a suitable classifier is utilized to identify the
type of an unknown instance.
The feature selection algorithms and the classifiers used in our method are presented as
follows:
Feature selection methods

Each instance in the breast cancer dataset consists of 13,582 genes. As shown later, all these
features are not informative for recognizing the breast cancer subtypes. As a result, feature
selection methods are used to find a suitable subset of genes in each step. In this model,
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different filter methods such as Information Gain (IG) [5], Chi-square [6], and Symmetrical
Uncertainty (SU) [7] are utilized in each step. We also propose new hybrid methods for
finding an optimal subset of genes.
Classification methods

SVM, Naı̈ve Bayes [8], random forest [21], and k-nearest neighbor (k-NN) classifiers have
been used in the literature [4], [10], [11], [12], [13], [14], [15]. In [16], SVM-L has been utilized
to predict the breast cancer subtypes. In this model, different classifiers are used to predict
subtypes in each step. Moreover, in the first and third steps of the proposed method, more
than one classifier such as SVM-L, SVM with polynomial kernel (SVM-P), SVM with Radial
Basis Function kernel (SVM-RBF), Sequential Minimal Optimization (SMO), and Random
Forest classifiers were used.
4.1.3

Results and experiments

In this section, we compare our model with existing work. To compare the performance of the
proposed model and SVM-RBF, we applied SVM-RBF without using any feature selection
algorithms and with Chi2 and IG methods on the breast cancer dataset. The results along
with the results of the proposed method are reported in Table 4.1. As shown in Table 4.1,
the proposed method achieves 100% accuracy which is 14.4% higher than the best accuracy
reported for SVM-RBF in Table 4.2 shows the result in each step in the tree model.
Table 4.1: Comparison of the proposed model with SVM-RBF and an existing model.
Model

Feature Selection

Genes#

A%

P

R

FM

SVM-RBF

-

All

77.85 %

0.802

0.778

0.749

SVM-RBF

Chi2

20

86.71%

0.866

0.867

0.864

SVM-RBF

IG

20

87.34%

0.872

0.873

0.872

Rezaeian et al [4]

Chi2

18

95.11%

0.951

0.951

0.951

Proposed

Proposed

18

100%

1.000

1.000

1.000
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Table 4.2: The Steps of the proposed model shows the biomarker genes and which class can be determined
at each step.
Step
Biomarker genes
Accuracy Classes
Step 1 AGR2, and TFF3
100%
Basel vs the
rest
Step2
HMGCS1, YBX1, C15orf39, HDAC11, and CTSF
100%
Her2 vs the
rest
Step3
CX3CL1, and ARAP3
100%
Normal
vs
the rest
Step 4 SPAG5, BUB1, MRPS23, CDKN3, ZFP36L2, 100%
LumbA
vs
CENPL, BOLA3, COX4NB, RNF2
LumbB

4.1.4

Discussion

Among the genes that have been identified by our proposed method for subtype classification and identification, several genes have been found to be involved in breast cancer. For
example, AGR2 is shown to be a promising drug target in breast cancer and can be served
as a useful prognostic indicator and biomarker in breast cancer metastasis [17]. TFF3 is also
a valuable predictive biomarker of endocrine response in metastatic breast cancer [18] [19].
YBX1 has been shown to have an important role in controlling MDR1 gene transcription,
which can provide a basis for the analysis of molecular mechanisms that are responsible for
intrinsic multi-drug resistance in breast cancer [20]. HDAC11 has been shown to play an
important role in cancer cell survival and may represent a novel drug target in oncology [21].
Moreover, it has been shown that the high expression of SPAG5 in tumour cells correlates
with aggressive tumours in breast cancer [22]. BUB1 plays an important role in breast
cancer proliferation and progression, and nuclear BUB1 immunohistochemical status has
been considered as a potential prognostic factor in patients with breast cancer [23]. Also,
dynamic changes in CDKN3 gene expression can predict prognosis of those breast cancer
patients that have been treated with tamoxifen [24]. Finally, gene ZFP36L2 has been shown
to be Estrogen Receptor β (ERβ) regulated in T47D breast cancer cell line [25].
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4.2

Hierarchical prediction model for treatments through out survivability

Although with the fast increase in breast cancer rates nowadays, the survival rates are also
increased not only due to the improvement in treatments, but also because of the new
technologies and enhanced research [26]. Breast cancer is still one of the leading causes of
women death worldwide. The survival rates vary with the treatment therapy, which includes
Surgery, Chemotherapy, Hormone therapy, and Radiotherapy. Patient response to treatment
varies from one patient to another [27]. Traditional laboratory techniques such as CAT scan
and Magnetic Resonance Imaging (MRI) provide useful but very little information, and
with the advances in DNA microarray technology which provide high throughput samples
of gene expression. Analyzing gene expression from breast cancer patients who undergo
different treatments provides a better understanding of the disease progression. A large
number of features complicates the computational model, and since it is much higher than
the number of samples, it creates a problem known as the curse of dimensionality, where
the standard classifiers struggle to handle the volume of features, and the model overfits
the data. Therefore, feature selection techniques are applied to solve the problem and filter
out irrelevant features. Mangasarian et al. utilized a linear SVM to extract six features
out of 31 clinical features; the data set contains samples from 253 breast cancer patients.
The model classified the samples into two groups. Node-positive in which the patients have
some metastasized lymph nodes, and node-negative for patients with no metastasized lymph
nodes. The six features were then used by a Gaussian SVM classifier to classify the patient
into three prognostic groups: negative, middle, positive. They found that patients in the
negative group had the highest survivability among the other groups, with the majority
of them having received chemotherapy as a treatment [28]. Using samples from patients
with high-risk clinical features in early stages of breast cancer, Cardoso et al. proposed a
statistical model to decide the necessity of chemotherapy treatment intervene from not based
on the expression of the gene [29]. In earlier work, we built a prediction model for survival
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based on different treatments without defining the period of survivability [30]; that is, given
a training set consisting of gene expression data of breast cancer patients who survived or
died after receiving a treatment therapy, we built a classifier model which predicted whether
a new patient survive or die. In this paper, we propose a classifier model to predict which
BC patient will survive beyond five years after undergoing a given treatment therapy. The
classifier model is built on top of a feature selection model, which identifies the genes which
can best distinguish among the survival classes.
4.2.1

Materials and methods

Samples from a publicly accessible dataset of 2,433 breast cancer patients and survival is
used to validate this approach [31]. After studying the given data, a set of six classes were
identified as the base of this work; these classes are the combination of each treatment
(Surgery, Hormone therapy, and Radiotherapy) with a patient statue (Living or Deceased).
The number of samples (patients) for each class are shown in Table 4.3, which indicates that
a total of 347 patients are used in this work.
Table 4.3: Class list with the number of saples in each class
Class
Living and Radio (LR)
Deceased and Radio (DR)
Living and Hormone (LH)
Deceased and Hormone (DH)
Living and Surgery (LS)
Deceased and Surgery (DS)
Total

Number of samples
132
19
20
6
130
40
347

Based on the available data, only three treatment therapies are covered which are Surgery,
Hormone therapy, Radiotherapy. Our proposed model is a hierarchical classifier that classifies
one versus the rest classes. The dataset contains unbalanced classes, a problem that is wellknown in machine learning. The pipeline starts with feature selection methods that include
Chi-square and Information Gain, which are applied for limiting the significant number
of features (genes). A wrapper method is also used to obtain the best subset of genes that
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represent the model by utilizing the minimum redundancy maximum relevance (mRMR) [32]
feature selection method. This step is followed by applying several class balancing techniques
such as SMOTE [33], cost-sensitive [34], and resampling [35] to balance the number of classes
before applying different types of classifiers such as Naive Bayes and Random forest. Finally,
a small subset of biomarker genes are recognized for predicting the proper treatment therapy.
To the best of our awareness, this work is the first prediction model which is built on the
combination of treatment and survivability of the patient as a class.
Multi-class classification model

We applied a multi-class approach, the one-versus-rest technique. This approach assumes
that one class is classified against the rest of classes, and then removed from the dataset.
Afterwards, we select another class to classify it against the rest and so on. Using a greedy
method to find the starting node, the method classifies all possible combinations such as ‘DH’
against the rest, then ‘DR’ against the rest, and so on for all the six classes. Afterwards,
the best starting node is selected as the root node of the classification tree based on the best
performance. Several classifiers were utilized to achieve these results such as random forest
and Naive Bayes. The classification model was built and tested with 10-fold cross-validation.
4.2.2

Results and discussion

The model of the multi-class is shown in Figure 4.1, which shows the final results for each
node and the performance measures that were considered such as accuracy, sensitivity, F1measure and specificity. The figure also shows the number of the correctly and incorrectly
classified instances in each node.
Moreover, Figure 4.1 also shows that the root node, DH against the rest, yields 100%
accuracy. The second node is obtained after removing the ‘DH’ instances from the data set
and then classifying each class against the rest. The best outcome was ’DR’ with accuracy
of 100%. We repeat the same process for the third node, finishing with ‘LH’ with accuracy
of 100%. Then, ‘DS’ in the fourth node with accuracy of 97.9%, sensitivity of 96.9%, and
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DH VS
Rest

NO

Yes
DH

Node1
DR VS
Rest

NO

Yes

Node2
LH VS
Rest

NO

Yes

Node3

NO

DS VS
Rest

Yes
DS

Node4

LR VS
LS
LS

Node5

Specificity 100%
Sensitivity 96.9%
F-Measure 98.5%
Correctly Classified 40
Incorrectly Classified 0
ICOSLG
SAR1A
PRPS1
FBRSL1
INPP5F
SFMBT2

Accuracy 80.9%

Accuracy 80.9%
Specificity 76.9%
Sensitivity 84.8%
F-Measure 81.8%
Correctly Classified 100
Incorrectly Classified 30

LR

Accuracy 97.9%

C14orf166
OSTC
ZFP91
AI376590
BU753119 OR2B3
ARPC3
DSCAM

Specificity 76.9 %
Sensitivity 84.8 %
F-Measure 81.8 %
Correctly Classified 112
Incorrectly Classified 20

LH
Accuracy 100 %

Specificity 100 %
Sensitivity 100%
F-Measure 100 %
Correctly Classified 20
Incorrectly Classified 0
DA874553
AKT1S1
CPPED1
BLP
ARFGAP2
VAMP4
CT47A1
CLASRP

DR

Accuracy 100%
Specificity 100%
Sensitivity 100%
F-Measure 100%
Correctly Classified 6
Incorrectly Classified 0

Accuracy 100 %
Specificity 100 %
Sensitivity 100%
F-Measure 100 %
Correctly Classified 19
Incorrectly Classified 0
ASXL1
WIPI2
ASAP1
ZNF121
METTL2A
FAM170B
BG944228
PDCD7
ATL1
TRPC5
FOSB
AL71228
BF594823
FBXO41

AKIP1
FGF16
AA884297
CDC42BPG
UPF3B
FAM114A1
OR2G6
ANKLE1
MGA
C14orf145

Figure 4.1: Multi-Class classification model with performance measures.

specificity of 100%, because all the ‘DS’ samples were correctly classified. In the fifth node, we
classify ‘LR’ and ’LS’; the accuracy drops down to 80.9%, because it is difficult to distinguish
between the living samples in both of them.
Overall, our method identified 47 gene biomarkers listed in Figure 4.1; a functional validation and biological insights were done for some of the genes by studying the information
provided in the literature and their relation to breast cancer.
Figure 4.2 shows that the gene expression of AKIP1 is up-regulated in the ‘DH’ samples
compared to the rest of the samples, while it shows that gene ASAP1 is down-regulated
in the ‘DR’ samples compared to the rest of the samples. ASAP1 has been reported to
be a breast cancer biomarker; it is precisely correlated with the invasive phenotypes that
have not been identified accurately [36]. Sabe et al. reported that ASAP1 is abnormally
over-expressed in some breast cancers and used for their invasion and metastasis.
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Figure 4.2: Box plots for the AKIP1 and ASAP1 genes in node number one and two, which show the minimum, first quartile, median, third quartile, and maximum gene expression values for each group of samples
(‘DH’ vs. Rest) and (‘DR’ vs. Rest).

4.3

An adaptive clustering algorithm for gene expression timeseries data analysis

Cancer is characterized by uncontrolled cell-growth in an organ. It starts when there is
an unpredictable change in the structure of DNA in a cell that creates a mutation. These
mutated cells divide out of control and crowd out the healthy cells in the body. Breast
cancer refers to a malignant tumor that has originated from the cells of the breast. It is
the most common female cancer in the Western world and one of the leading causes of
death by cancer among women. It stands second among the most prominent causes of death
amongst the middle-aged women in the world and most common in women over 50 years of
age [37–40]. Mutations in a small number of genes, oncogenes or tumor suppressors, whose
change deregulate many biological processes leads to initiation and progression of breast
cancer as well as resistance to treatment [41]. The biomarker is defined as a measurable
indicator of a biological process. The discovery of biomarkers can be a crucial step in
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Figure 4.3: Circos plot for the biomarker genes in node number one for the Rest samples based on the
correlation coefficient among genes expressions (p < 0.05).
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predicting survivability and handling of any disease. Gene expression values are different in
various stages of progression of the disease. One of the most powerful applications of gene
expression analysis is to identify biomarkers that can be used for disease risk assessment,
early detection, prognosis and preventive measures [42]. Genes tend to under-express or overexpress during progression and recurrence of any disease, especially cancer. The problem of
choosing those biomarker genes that provide insights about the disease poses a challenging
problem in high-dimensional data.
Clustering time-series methods have been used in bioinformatics mainly for gene expression profiles [43, 44]. Rueda et al. proposed a clustering method that, first, aligns the gene
expression profiles together to minimize the total area between the gene profiles, and then
cluster the profile using an agglomerative clustering method based on the furthest-neighbor
distance between each pair of clusters as in Chapter 3. Also, they used a modified version
of I-index to validate the optimum number of clusters.
In this section, we propose two methods to identify the genes that are dissimilar, as outlier
genes that could serve as potential biomarkers. Outliers can be of two types, local outliers
and global outliers. Figure 4.4 depicts global and local outliers. Let us consider the curves
in Figure 4.4 as gene expression profiles. From the beginning, the curve in red clearly trends
different from other curves. Thus, this is a global outlier. The curve in yellow follows a
similar trend with other curves up to a certain point (represented by dotted lines) and starts
following a different trend. This is called a local outlier.
The local and global outlier genes could serve as potential biomarkers since they follow a
different trend than the other genes in the background, which may give a biological insight
of the relationship between those abnormal expressions of the outliers and breast cancer
progression.
4.3.1

Data pre-processing

For this work, we have used the METABRIC dataset, which is publicly available at cBioPortal. This dataset contains clinical data (Patient ID, survival status, overall survival in
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Figure 4.4: Local and global outliers.

months and type of treatment) for a total of 1,904 patients. Of these, 480 patients were
diagnosed/treated for breast cancer but died because of some other reason; thus, we filtered
them out as they will have no relevance to our problem of predicting biomarkers of survivability. That gives us a total of 1,424 patients; from which we consider only the patients
who are still living and disease free, 801 patients, to predict biomarkers of survivability. The
dataset also has expression data (24,368 genes determined through microarray) for all the
patients in the clinical dataset.
This work, to the best of our knowledge, is the first to assume that, overall survival of
cancer patients are time points to approximate disease progression. This assumption is based
on the fact that any biological function is a continuous process and breast cancer is not an
exception. Previous work on detecting biomarkers at a gene level was focused on grouping
up of similar gene expression profiles and eliminating the outlier genes as noise.
First, the two datasets (clinical dataset and the gene expression dataset) were merged with
the KEY = PATIENT-ID, and next, we create a time-series. A time-series is a sequence
of measures at specific time points. Gene expression of cancer patients can be measured at
different time points. Also, time points can be interpolated to approximate the growth of
disease over time and isolate outliers.
Figure 4.5 depicts the process by which our time series data were created. The dataset
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Figure 4.5: Dataset pre-processing.

has patients overall survival (the day patients were diagnosed with breast cancer to the day
the dataset was created) in months. In this work, we assume that the survival periods of each
patient as time-series bins. The shortest time of patient who survived is one month and the
longest being 342. To create the time-series data, we partition the time axis into survival
bins of length six months. We chose an interval of 6 months since the average time for
progression of cancer is six months. Also, for a cancer patient who is undergoing treatment,
it takes at least 3-6 months to respond to it. For the dataset we have, time series starts
from 1-6 months, 7-12 months and go on until 337-342, giving us 55 time points. Next, we
average the gene expression levels over all the patients appearing in a survival bin.
4.3.2

Methods

After creating the time-series dataset, we approximate the progression of each gene expressions throughout 55 time points using cubic spline interpolation. After universally aligning
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gene expression profiles, we clustered them using an agglomerative clustering approach based
on the area between the profiles as a distance measurement.
Natural cubic spline interpolation and universal alignment of gene profiles

Gene expressions throughout the time points are natural cubic spline interpolated to create
a trending profile for each gene in the given dataset. Then, the profiles were universally
aligned by shifting the interpolated gene profiles vertically in such a way that the squared
error between any two of those profiles is minimal as mentioned earlier in Chapter 3.
Clustering algorithm

The main objective of using clustering here is to filter out the profiles that trend differently
from other profiles [45–47]. In this work, we have chosen singleton clusters as outliers. We
also choose clusters with a very small number of profiles that follow the same trend with
profiles within the cluster and dissimilar from other profiles in a different cluster. Hierarchical
agglomerative clustering is a bottom-up approach. Initially, each profile in the dataset is
an individual cluster (each profile is a cluster), and then the clusters are merged based on
the distance between them. Here, the clusters are combined based on the complete linkage
criteria (computing the distance between the furthest pair of points for each pair of clusters
and combines the pair of clusters that has the minimum furthest distance among all such
distances). The merging process continues until the desired number of clusters is reached.
This approach places the profiles with similar trends into one cluster and filters out profiles
that are less similar to other profiles as one or more different clusters.
Profile alignment and agglomerative clustering index

Profile alignment and agglomerative clustering Index (PAAC) is the validity index that has
been used to determine the desired number of clusters for the dataset. PAAC is a modified
version of the I-index. IPAAC index is the modified version of the I-index formula to reduce
the impact the I-index value faces when many clusters are used in it as follows:
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k is the number of clusters, q is the coefficient of normalizing the number of clusters, p is
the coefficient of the degree of the index, µij = 1 if gene j belongs to the ith cluster; otherwise
µij = 0, µi is the center of ith cluster, n is the number of genes, and d(., .) is the distance
between the profiles. The aim here is to choose the value of k, that has the maximum value
of I-index as the desired number of clusters for the dataset.
Baseline method

In our baseline method, the entire time-series dataset (time point 1 to time point 55) is
universally aligned towards the universal profile z(t). Then, we use hierarchical clustering
to detect the gene profiles that trend differently from others. Finally, we use cubic spline
interpolation to identify singleton clusters that trend differently from other genes as outliers.
Figure 4.6 depicts the work flow of our baseline method.
Adaptive clustering algorithm

We propose an iterative adaptive clustering algorithm (ACTS) wherein we slice the time-axis
into distinct intervals based on three parameters, window size, outlier threshold and step size
as seen in Figure 4.3.2. To detect the local outliers, it is essential to slice the time-series data
and perform the clustering algorithm on each interval separately and identify the outliers
based on the partial clustering results. Partially clustering the dataset makes our algorithm
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Figure 4.6: Work flow of baseline method.

Figure 4.7: Slicing the time series based on window size and step size.

to adapt to the structure of data in a specific interval and identifies the genes that are more
relevant to breast cancer survivability.
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Figure 4.8: Window size and step size.

Window size for the first iteration

Window size for the first iteration/interval is decided based on visualizing the data. This
parameter is dynamic and highly dependent on the structure of the dataset. We choose
the window size in such a way that the interval has considerable gene expression variability
among the genes and, many visible peaks which could be potential outliers. A disease like
cancer during the progression has several genes that are over-expressed in the initial stage
of the disease. Thus, the main idea here is to pick many observations/genes that trend
differently from others in the first Iteration. Once we determine the window size for the first
iteration, the algorithm proceeds as follows:
• Extract data based on the window size from the time-series dataset.
• Perform multiple profile alignment and clustering to detect potential biomarkers within
that interval. In Figure 4.8, based on visualization, we choose window size = 8 time
points for the first iteration in our time-series dataset.
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Figure 4.9: Change in gene trend.

Step size = 2

Step size here is a fixed parameter and is used from the second iteration onwards until the
last time-point in the dataset. Genes that are outliers trend differently from others. We
investigated all possible trends which a gene could follow, to be captured as an outlier.
In Figure 4.9, the lines colored in red depict all possible trends a gene could follow during
progression. Based on this observation, we need to identify the trend of a gene in at least two
time points to determine if it is an outlier in an interval. From the second iteration onwards,
the step size is used to include new time-points from the dataset for the next consecutive
iterations until the last time-point is reached. After the first iteration, we proceed with
the algorithm based on step size = 2. Figure 4.8 also depicts how step size is used in our
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time-series dataset. From the second iteration until the end, the algorithm proceeds as
follows:
• Adds two points after each iteration until the last time-point in the dataset.
• Performs multiple profile alignment and clustering on each interval until the end.
Outlier threshold

Outlier threshold is an arbitrary parameter used to determine and limit the number of genes
in a cluster that can be filtered out as outliers. Alkhateeb et al. used a threshold of one gene
in a cluster (singleton clusters) [45]. In our case, it is difficult to determine the local outliers
with a threshold of one gene in a cluster. With specific time intervals, it is not easy to filter
out singleton clusters as there could be many genes following a similar trend. Thus, we set
a threshold of ≤ five genes in a cluster for filtering out the outliers and reduce redundancy
in each iteration. By grouping genes that have very high similarity (similar trends) to each
other, the algorithm ensures minimum inter-cluster dissimilarity and maximum intra-cluster
dissimilarity among the clustered data.
Workflow of proposed algorithm

Figure 4.10 depicts the work flow of the proposed algorithm. The proposed algorithm uses
an iterative approach to detect outliers as biomarkers. We first slice the time-series dataset
based on two parameters, window size and step size. Window size is chosen in a way that
covers the interval that has the largest variation among genes. Step size here is a fixed
parameter, which is equal to two. Outlier threshold is an arbitrary parameter used to
limit the number of outliers in each interval. Then, we use hierarchical clustering and spline
interpolation methods to detect outliers on each sliced interval based on an outlier threshold.
Algorithm 1 is the pseudo code for the ACTS.
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Figure 4.10: Workflow of ACTS

Algorithm 1 ACTS pseudocode.
Input: Time-Series Dataset,Window size, Step size, Outlier Threshold, k range
Output: Outliers in each interval
1: input1 = Time-series Dataset (1:W indowsize)
2: clustering and PAAC(input1)
3: repeat
4:
input2 = new dataset;
5:
clustering and PAAC(input2)
6: until last time point is reached
7: function clustering and PAAC(input)
8:
for each gene in input do
9:
uni-align = Align each gene towards universal profile z(t)
10:
end for
11:
for each value in k range do
12:
perform Hierarchical Agglomerative Clustering of uni-align
13:
perform PAAC to determine the best k value
14:
end for
15:
Choose k value for max(PAAC)
16:
plot cubic spline Interpolation for best k value clustering result
17:
if Cluster size ≤ OutlierT hreshold then
18:
filter genes in cluster as outliers
19:
else
20:
new dataset = Add time-points based on Stepsize for next iteration.
21:
end if
22: end function
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4.3.3

Comparison with other methods

We tried to utilize a bi-clustering method called BiGGEsTS [100, 101], which created
679,107 bi-clusters for our time-series dataset. The tool did not detect any outliers and
is not flexible enough to let us download the data created in each bi-cluster. We had to
visually check the bi-cluster to compare the outlier genes from ACTS.
4.3.4

Results

With parameters q = 0.7, p = 2, k = 46 clusters, our baseline method detected 24 local
outliers (as singleton clusters) of which 14 genes were related to breast cancer survivability.
ACTS with parameters, window size for interval-1 set to 8, step size set to 2 from interval-2
onwards, outliers threshold on each interval ≤ 5, detected 53 outliers. Out of 53, 46 of them
were related to breast cancer. ACTS yields an accuracy of 86.7% in terms of clustering the
potential biomarkers of breast cancer survivability. We identified 24 oncogenes and 18 tumor
suppressor genes. Table 4.4 shows the results of baseline method and Table 4.5 shows the
results of ACTS.
Biological insight

With the help of previous literature, we observe the biological significance of all genes obtained as potential biomarkers of breast cancer survivability:
Baseline method

• PSAP are related to breast cancer recurrence and potentiating resistance to breast
cancer treatment [48].
• CD81 is a biomarker responsible for cancer proliferation [49].
• EEF1A1 is an oncogene, a potential oncoprotein that is over-expressed in about twothirds of breast tumors [50].
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Table 4.4: Result of baseline method.
S.No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Gene
HIST1H4C
ATP5EP2
PSAP
CD81
RPS5
EEF1A1
PYY2
HES7
ZNF678
ATP5B
RPL11
RPS20
SNRPD2
RPL32
HSP90B1
TOMM7
UBA52
BGN
RPS15
RPL12
TIMP1
RPS16
FTL
RPL10

Related to BC
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

• HES7, SNRPD2, UBA52, RPL12 are genes that can affect the survival rate of
breast cancer patients if highly expressed [51–55].
• RPL11, TIMP1, FTL and RPL32 are biomarkers of breast cancer development
[56–58].
• HSP90B1 is an oncogene that is associated with breast cancer metastasis and decreased
survival [54].
• BGN is used for subtype-specific classification [59].
• RPS16 is MicRNa target to improve the efficacy of cancer therapy [Jezequel et al.,
2012].
• Oncogenes: SCGB2A2, ANKRD30A, SCGB1D2, SCGB2A1, TFF3, KRT81, CSN3,
KLK5, C4orf7, BEX1, UGT2B11, UGT2B7, LTF, UGT2B28, PROM1, KRT7, SER83

PINA6, CPB1, RAMP1, CST1, FLJ23152, S100A9, S100A8 [59–78].
• Tumor Suppressor Genes: TAT, BAMBI, VTCN1, HLADRB1, PXDNL, DIO1,
HSPB8, CYP4X1, HMGCS2, CYP4Z1, TFAP2B, TFF1, GRIA2, EEF1A2, BMPR1B,
MYBPC1, SLC27A2, SERPINA5 [79–95].
• SYT13: & TUBA3D are associated with ER specific cancer [96, 97].
• TCN1: Patient will have adverse effects on treatment if this gene is highly expressed [98].
• S100P: Survival rate is decreased if this gene is highly expressed [99].
• PIP:
1. regulates proliferation of luminal-A type breast cancer cells in an estrogen-independent
manner [88].
2. ER+ breast cancer, particularly those with very high level of ER expression, PIP
appears to play an important role in proliferation and invasion as well as acquired
resistance to tamoxifen [89].
3. Biomarker in breast cancer micrometastasis [90] and outcome prediction in breast
carcinoma [78].

Discussion

Figures 4.11 and 4.12 depict the heatmaps for oncogenes and tumor suppressor genes from
ACTS. Most of the oncogenes were over-expressed in the first and last few time-points. Some
tumor suppressor genes are under-expressed at the beginning, and most of them are overexpressed at the end. The activity of tumor suppressor genes towards the end satisfies the
biological meaning of cancer, suggesting that the down-regulation of a set of genes may be
the underlying mechanism of cancer formation, while the up-regulation may characterize and
possibly control the state of evolution of individual cancers. Initially, the activity of tumor
suppressor genes was low, resulting in high activity of oncogenes, and hence the progression
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Figure 4.11: Heatmap for 24 oncogenes.
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Figure 4.12: Heatmap for 18 tumor suppressor genes.
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of the disease. Towards the end, more tumor suppressor genes are activated which neutralizes
the effect of oncogenes helping in patients increased survivability rate.
Since we know precisely at which time-point an oncogene is over-expressed, we can direct
or target treatments towards it to reduce/control their high activity which could improve
patients overall survivability. At the same time, any efforts to trigger or enhance the activity
of tumor suppressor genes could also contribute to increasing the rate of survivability during
treatment.
Conclusion and future work

We proposed an innovative approach to detect outliers (genes that trend differently from
the majority of other) as biomarkers of breast cancer survivability using a time-series model.
These biomarkers can be used to predict and improve patient survival, diagnosis, and therapy
for breast cancer. First, we created a time-series dataset using patients overall survival.
Then, we grouped patients into survival bins based on their survival in months and averaged
the gene expression level of all the patients in each survival bin. Initially, we found global
outliers using all the time points from the time-series dataset. Then, we sliced the time
series dataset with a sliding window approach to create gene-expression data on specific
intervals and used profile alignment and agglomerative clustering in each interval to detect
local outliers. Finally, we found the biological relevance of genes closely related to breast
cancer survivability suggesting them as potential indicators for wet-lab experiments. Our
algorithms detected 60 genes related to breast cancer survivability including 36 oncogenes
and 18 tumor suppressor genes. In this work, we have used the data from living patients in
the dataset. As future work, we plan to extend ACTS to the patients who died to pick more
indicators. Then, we can compare the two results (outliers from living and dead datasets)
and pull meaningful insights. We are also planning to try the same approach on a different
cancer dataset. e.g., prostate cancer data.
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Table 4.5: Results of ACTS method.
S.No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

Gene
1..8

1..10

1..12

1..18

1..20

1..34

1..36

1..50

Related to BC
SCGB2A2
ANKRD30A
SCGB1D2
SCGB2A1
PIP
TFF3
KRT81
CSN3
KLK5
C4orf7
TAT
BEX1
UGT2B11
UGT2B7
LTF
UGT2B28
LOC338579
PROM1
BAMBI
VTCN1
KRT7
DQ893812
HLA-DRB1
DB005376
SERPINA6
PXDNL
CPB1
DIO1
HSPB8
RAMP1
CST1
FLJ23152
CYP4X1
HMGCS2
CYP4Z1
TFAP2B
PPP1R1B
TFF1
GRIA2
EEF1A2
BMPR1B
CLIC6
TCN1
MYBPC1
CNTNAP2
S100A9
S100A8
S100P
SLC27A2
PHGR1
SYT13
SERPINA5
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X
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X
X
X
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X
X
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Chapter 5

Transcriptomics signature from next
generation sequencing data reveals
new indicators related to prostate
cancer
Prostate cancer is one of the most common types of cancer among men worldwide. It is
estimated that more than one in 1.2 million men have been diagnosed with prostate cancer
in 2015, resulting in more than 335,000 deaths [1]. A current obstacle in improving patient
care is the inability to accurately predict tumors that are at a high risk for progression.
Identifying reliable prognostic biomarkers to guide treatment decisions is a high priority in
the prostate cancer field.
Next-generation sequencing has revolutionized genomic and transcriptomic analysis. RNASeq reads the transcriptome at a single-nucleotide resolution, revealing unexplored genomic
and transcriptomic territories not revealed using conventional technologies, such as microarray [2,3]. RNA-Seq represents a high-throughput technique capable of identifying nonconventional biomarkers, such as noncoding RNA and alternative splicing events [2, 3]. Alternative
splicing can produce protein isoforms with potentially different functions from the same
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DNA sequence. Indeed, approximately half of all active splicing events are altered in ovarian
and breast tumors [4]. RNA-Seq can also measure transcriptomic activity and transcriptome assembly to provide better understanding of the regulation of corresponding protein
isoforms [5–8]. A typical RNA-Seq experiment, however, produces a large amount of data
and, therefore, demands considerable computational resources in both time and space. Using
machine learning to analyze RNA-Seq data can reduce redundant and irrelevant information
while providing a selection of potentially significant biomarkers for biological validation. Optimizing a computational approach to effectively isolate novel splice variants from RNA-Seq
data may provide invaluable clues about novel biomarkers for detecting and predicting the
progression of prostate cancer. Several studies have used RNA-Seq to identify new potential
biomarkers for prostate cancer. Feng et al. presented a comprehensive review of the most
recent studies on alternative splicing in cancer using RNA-Seq data [9]. This included an
overview of several publicly available RNA-Seq datasets and the most recent open-source
bioinformatics tools for RNA-Seq data analysis. Recent studies using RNA-Seq for prostate
cancer analysis include genome-wide association and variation studies, non-coding RNAs
(e.g., microRNA, lincRNA and siRNA), somatic mutations, chimeric RNA and gene fusion.
Kannan et al. used RNA-Seq on 20 human prostate cancer and 10 matched benign prostate
tissues from patients who had received no preoperative therapy prior to radical prostatectomy and identified a potential link between increased chimeric RNA events and prostate
cancer [10]. Pflueger et al. used RNA-Seq data from 25 human prostate cancer samples
and isolated 7 novel gene fusions related to prostate cancer, including TMPRSS2-ERG [11].
TMPRSS2-ERG gene fusion is present in 50–90% of human prostate cancers and has been
identified as an early molecular event associated with invasion of the disease [12]. Ren et
al. also identified recurrent gene fusions in 14 primary prostate tumors from a Chinese population found TRMPRSS2-ERG fusion to occur at a very low frequency but isolated two
novel gene fusions, CTAGE5-KHDRBS3 and USP9Y-TTTY15, that occurred frequently in
the Chinese cohort. These conflicting reports illustrate that disparity exists among prostate
cancer patients of different ethnic backgrounds In another study [13], Xu et al. identified
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92 new genes with somatic mutations in human prostate cancer study used RNA-Seq data
from five cancer patients to detect variants of chromosomal rearrangements, insertions and
deletions of significance [14], they identified a frame-shift mutation in the coding region of
TNFSF10 that disrupts its ability to induce apoptosis, a change that may promote tumor
progression. Prensner et al. focused on new noncoding RNA and found an unannotated lincRNA, PCAT-1, a prostate-specific regulator of cell proliferation [15]. Exploiting the highresolution features of RNA-Seq that allow for reconstructing the transcriptome, inferring
protein isoforms and the corresponding protein function can offer an integrative approach to
better understanding the onset and progression of disease. Thus, in this study, we propose
a new model for detecting differential splice junctions in prostate cancer using RNA-Seq
data. This model identifies transcripts associated with malignant tumors as compared to
corresponding matched normal samples and transcripts that are differentially expressed during the disease progression. Our analysis revealed several transcripts that can be used as
potential biomarkers for predicting prostate cancer and disease progression.

5.1

Materials

We used three datasets, Kim’s [16] Ren’s [13], and Kannan’s [10] each containing matched
normal versus malignant prostate cancer tumor samples. Ren’s dataset used random hexamer primers, while the other datasets used oligo (DT) primers. All these datasets are in
sequence read archive (SRA) file format and are publicly available from the national center
for biotechnology information (NCBI) repository. Table 1 shows the number of samples in
each dataset.
In addition, we used the dataset from Long et al. [17], which contains prostate cancer
progression stages using 104 samples from 100 patients. Table 5.1 shows the distribution of
samples across various stages of prostate cancer in this dataset.
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5.2
5.2.1

Methods
Genome mapping and transcriptome assembly

Figure 5.1 shows the pipeline of our proposed model. Initially, samples are pre-processed
individually by mapping the mRNA reads of each sample to the Human Genome (hg19)
using Tophat2 [18] and Bowtie2 [19], two fast methods for mapping splice junctions and
aligning short reads, respectively. In the next step, we use Cufflinks [6] for assembling the
transcriptome using the mapped reads from the previous step based on RefSeq annotation
[20]. Cufflinks computes all transcript abundances in terms of FPKM values (fragments per
kilobase of exon per million of mapped reads) for each transcript in each of the samples.
Both Tophat2 and Cufflinks were run using default parameters.
5.2.2

Finding differentially expressed transcripts

The deliverables of our study two-fold. First, we aim to identify a gene signature that predicts
prostate cancer by comparing cancer versus their matched normal counterparts. Secondly,
we focus on differential expression of gene transcripts in a pairwise analysis of various stages
of prostate cancer progression. Using the latter, we anticipate that this type of analysis will
reveal gene transcripts that are potential markers for prediction of disease progression.

Table 5.1: Datasets used in this study for malignant vs. normal analysis with the number of samples in each
dataset.
Dataset

Kim
Ren
Kannan

# of Tumor Samples
Malignant Matched
Normal
7
4
14
14
10
10
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Reference

[17]
[13]
[10]

Figure 5.1: - A Schematic view of the proposed workflow for finding differential transcripts between benign
vs. malignant and across various stages of prostate cancer
Normal versus malignant

We consider the identification of differentially expressed transcripts in normal versus malignant prostate cells as a two-class classification problem, where each transcript is used as a
feature along with FPKM as feature value. After obtaining the transcripts using cufflinks,

Table 5.2: Distribution of Long’s dataset samples in various stages of prostate cancer.
Prostate Description
stage
T1c
The tumour is not detectable via imaging techniques, but it is detectable
using a needle biopsy performed due to an elevated serum PSA
T2
The tumour is palpable, but confined to the prostate
T2a
The tumour is in half, or less than half, of one of the prostate glands two
lobes
T2b
The tumour is in more than half of one lobe, but is not in both lobes
T2c
The tumour is in both lobes but confined within the prostatic capsule
T3
The tumour start spreading out of the prostate tissue
T3a
The tumour has spread through the prostatic capsule on one or both sides,
but has not spread to the seminal vesicles
T3b
The tumour has invaded one or both of the seminal vesicles
T4
The tumour rises to other organs
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# Patients
14
10
23
11
30
2
6
8
1

we used minimum Redundancy Maximum Relevance (mRMR), which is a greedy feature
selection method that incorporates a classifier to find a subset of features that accurately
classify the samples. After feature selection, we applied different algorithms to find the most
accurate classification of the different stages/substages. A significantly smaller number of
features allowed us to use several classifiers and optimize their parameters. The classifiers
used for comparison include support vector machine (SVM) [26] with the radial basis function (RBF), linear and polynomial kernels, random forest [21], decision tree [22] and naı̈ve
Bayes.
Prostate cancer progression

To identify differentially expressed transcripts in prostate cancer progression, we formulated
the problem by following a multi-class supervised classification model. The samples were
grouped based on pairs of consecutive stages/sub-stages (T1c, T2, T2a, T2b, T2c, T3,
T3a, T3b and T4) as outlined in Table 4.4. To formulate the multi-class classification
problem, each sample contains the FPKM values for each transcript as features, and each
pair of consecutive stages/sub-stages serve as class labels. Since some stages, such as T3
and T4, contain a small number of samples, the ability of the classifier to retrieve the
discriminative power of the data would be reduced. In addition, the classifier may lose
generalization power, and hence may cause overfitting. Therefore, to compensate for this
imbalance, stage T3 samples were merged with T3a samples and stage T4 with T3b samples.
Furthermore, we combined stages T3, T3a, T3b, and T4 samples into a single group and
named it as T3/T4 to study the transcripts expression in the latter stages of progression
versus T2c. Reconstructing the transcriptome for all samples using Cufflinks resulted in
43,497 transcripts or features to be considered in the classification model. As this number is
prohibitive for a typical classification algorithm, we applied feature selection to reduce the
dimensionality of the problem, and to improve the performance of the model, while delivering
a set of meaningful transcripts as potential biomarkers. Transcripts were filtered following a
wrapper feature selection approach that uses mRMR. The classifier we used was SVM along
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with the linear kernel with normalization. The wrapper feature selection algorithm was run
on the well-known data mining tool Weka [23]. Optimizing the parameters of the SVM in
the wrapper-based approach for feature selection on 43,497 transcripts would be a daunting
task. Thus, the linear SVM was selected as the wrapper method because it yields accurate
and fast classification, while using default parameters.

5.3

Results

Using the proposed model, we conducted two different experiments: First, on malignant
tumors versus their matched normal counterparts and, second, on samples from various
stages of prostate cancer progression.
5.3.1

Malignant versus matched normal comparison

We tested and validated our proposed wrapper-based feature-selection method on three
different datasets (Kannan’s, Kim’s and Ren’s datasets). Table 5.3 and Figure 5.2 show the
differentially expressed transcripts (i.e., malignant versus normal) identified in each dataset.
Two of the identified transcripts (NM 019024 and NM 001242889; corresponding to genes
HEATR5B and DDC, respectively) were common between Kannan’s and Kim’s datasets,
whereas one identified transcript (NR 024490; corresponding to the gene GABP B1 − A51)
was common between both Kim’s and Ren’s datasets.
Figure 5.3 shows the average of transcript abundance for malignant versus matched normal
samples. The bars represent mean FPKM values for the three common transcripts selected.
The averages of FPKM values were calculated for both malignant and matched normal
samples in the three datasets in such a way that the result of each dataset are comparable on
an uneven field. Transcript NM 001242889 (DDC) was found to be differentially expressed in
malignant samples compared to matched normal samples. DDC has previously been shown
to be over-expressed in cancer samples compared to their matched normal samples. Similar
patterns were observed in our results, which suggests that DDC gene is a relevant biomarker
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for prostate cancer.
Figure 5.4 shows the performance of five different classifiers on discriminating malignant
samples from their matched normal counterparts in the three datasets. The classifiers were

Figure 5.2: Genes corresponding to the differentially expressed transcripts identified in Kannan’s, Kim’s and
Ren’s datasets.

Figure 5.3: Expression trend of matched normal versus malignant transcripts.
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trained with default parameters and validated via the 10-fold cross validation approach.
We used accuracy (ACC) and area under ROC curve (AUC) to evaluate the performance
of the classifiers, which show that the SVM classifier with a linear kernel outperformed all
other classifiers for the three datasets. These classification results show that using a handful
of transcripts – less than ten for each dataset – malignant tumors can be easily identified
with almost perfect accuracy, in most cases. This has an important implication in clinical
contexts, by virtue of the fact that effective and simple tools for diagnosis and prognosis of
the disease can be developed.
The results of applying mRMR feature selection to identify the top discriminative transcripts between pairs of consecutive stages was compared to the results obtained after applying CuffDiff [6], a tool that uses statistical methods to identify differentially expressed
transcripts. In each pair of consecutive stages, the proposed model identified fewer selected

Table 5.3: Differentially expressed transcripts identified in Kannan’s, Kim’s and Ren’s datasets.
Dataset

Transcript ID

Kannan
[10]

Kim
[17]

Ren
[13]

Gene Name

Description

NM 019024

Transcript
Type
mRNA

HEATR5B

HEAT repeat containing 5B

NM 001242889

mRNA

DDC

NM 152228
NM 001204401

mRNA
mRNA

TAS1R3
XIAP

NR 024490

LncRNA

GABPB1-AS1

Dopa decarboxylase, transcript variant 6
Taste 1 receptor member 3
X-linked inhibitor of apoptosis, transcript variant 2,
GABPB1 antisense RNA 1

NM 001242889

mRNA

DDC

Nm 019024
NM 032415

mRNA
mRNA

HEATR5B
CARD11

NR 024490

LncRNA

GABPB1-AS1

NM 000424
NM 001128826

mRNA
mRNA

KRT5
NCS1

NM 000494

mRNA

COL17A1

NM 000700
NM 005567

mRNA
mRNA

ANXA1
LGALS3BP
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Dopa decarboxylase, transcript variant 6
HEAT repeat containing 5B
caspase recruitment domain
family member 11, transcript
variant 2
GABPB1 antisense RNA 1
Keratin 5
Neuronal calcium sensor 1,
transcript variant 2
Collagen type XVII alpha 1
chain
Annexin A1
Galectin 3 binding protein

transcripts as compared to the CuffDiff model (Table 11). We evaluated the performance of
the two aforementioned models using different performance measures that include Accuracy
(ACC), F-measure (FM), Matthews correlation coefficient (MCC) and Area under curve
AUC. For classification, we used the cost sensitive meta-classifier model along with random
forest classifier (100 trees) with the same settings for both models. In each case, we obtained
a much higher performance using transcripts selected from our feature-selection method
rather than that of CuffDiff. Importantly, we observed no overlap between transcripts detected by the two models, stressing the importance of the new method for isolating hits as
biomarkers for progression of prostate cancer. Table 5- Top transcripts that discriminate
stages T2 and T2A of prostate cancer
Figures 5-11 depict transcripts listed in Tables 4-10, respectively, across different stages

Figure 5.4: Performance of five different classifiers for matched normal versus malignant classification.
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of prostate cancer. The x-axis shows the stages of prostate cancer, while the y-axis shows
the median of FPKM values of samples in each stage. Of particular interest are transcripts
that are significantly altered at the critical transition from stage T2 to T3/T4 (Figures 9

Table 5.4: Top transcripts that discriminate stages T2 and T2A of prostate cancer.
Transcript
NM 004860

Chr.
17

Type
mRNA

NM 052850

19

mRNA

NM 001272095 16
NM 001261390 17

mRNA
mRNA

NM 153274
1
NM 001252641 19

mRNA
mRNA

NR 038352

ncRNA

5

Description
Fragile X mental retardation, autosomal homolog 2
Growth arrest and DNA damageinducible, gamma interacting protein 1
Syntaxin 4, transcript variant 1
Calcium binding and coiled-coil domain 2, transcript variant 1
Bestrophin 4
Prefoldin-like chaperone, transcript variant 3
Decapping mRNA 2, transcript
variant 3

Gene
FXR2
GADD45GIP1

STX4
CALCOCO2
BEST4
URI1
DCP2

Table 5.5: Top transcripts that discriminate stages T2A and T2B of prostate cancer.
Transcript
NM 032023

Chr.
10

Type
mRNA

NM 080792

20

mRNA

NM 000095
NM 003102
NM 080797

19
4
20

mRNA
mRNA
mRNA

NM 002725

1

mRNA

Description
Ras association (RalGDS/AF-6) domain family member 4
Signal-regulatory
protein
alpha
(SIRPA), transcript variant 3
Cartilage oligomeric matrix protein
Superoxide dismutase 3, extracellular
Death inducer-obliterator 1, transcript
variant 3
Proline/arginine-rich end leucine-rich
repeat protein, transcript variant 1

Gene
RASSF4
SIRPA
COMP
SOD3
DIDO1
PRELP

Table 5.6: Top transcripts that discriminate stages T2B and T2C of prostate cancer.
Transcript
NM 001711
NM 032023

Chr.
X
10

Type
mRNA
mRNA

NM 001014443

1

mRNA

NM 021724

17

mRNA

NM 012098

9

mRNA

Description
Homo sapiens biglycan
Ras association (RalGDS/AF-6) domain family member 4
Ubiquitin specific peptidase 21, transcript variant 3
Nuclear receptor subfamily 1, group
D, member 1
Angiopoietin-like 2
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Gene
BGN
RASSF4
USP21
NR1D1
ANGPTL2

and 11). DOCK9 (Figure 9) and FLVCR2 IK2F3, USP13, PTGFR, CLASP1 (Figure 11)
are all transcripts that significantly increase at the T2 transition and remain elevated in advanced prostate cancer stages. These may represent novel indicators – either individually or
combined as a signature. They may also represent novel targets for therapeutic intervention.

5.4

Conclusion and discussion

Identifying novel biomarkers to clearly distinguish between low and high-risk prostate cancer
progression is a very important step toward directing treatment strategies that are efficacious
yet minimally invasive. Using the power of next generation sequencing technologies and
machine learning techniques, we found several transcripts that have the potential to serve as
prognostic indicators in guiding treatment decisions. These transcripts constitute a genomic
and transcriptomic signature of prostate cancer and its progression, which has never been
Table 5.7: Top transcripts that discriminate stages T2C and T3A of prostate cancer.
Transcript
NM 001198979

Chr.
1

Type
mRNA

NM 001099285

2

mRNA

NM 001198899

1

mRNA

NM 001130048

13

mRNA

NM 000899

12

mRNA

Description
Small ArfGAP2 (SMAP2), transcript variant 2
Prothymosin, alpha (PTMA), transcript variant
1
YY1
associated
protein
1
(YY1AP1),
transcript
variant
6
Dedicator of cytokinesis 9 (DOCK9),
transcript variant 2
KIT ligand (KITLG), transcript
variant b

Gene
SMAP2
TMSA

YY1AP1

DOCK9
KITLG

Table 5.8: Top transcripts that discriminate stages T3A and T3B of prostate cancer.
Transcript
NR 034169

Chr.
2

Type
ncRNA

NM 015380

22

mRNA

NR 046417

15

ncRNA

Description
Family with sequence similarity 133,
member D
SAMM50 sorting and assembly machinery component
Olfactory receptor, family 4,
subfamily F, member 13,
pseudogene
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Gene
FAM133DP
SAMM50
OR4F13P

characterized before. Further studies using wet-lab experiments and clinical assays will
be important to confirm the presence of these indicators in particular biological processes
involved in the disease and its progression. Some of our isolated genes have previously been
linked to other forms of cancer. For example, NREP (P311) is a transcript upregulated
in stages T3 to T4 as compared to T2c. Although there are no published reports on the
role of NREP on prostate cancer, it has been shown to be involved in glioma motility
and invasion via the reorganization of the actin cytoskeleton at the periphery of these cells
[24]. Upregulation of NREP expression from stages T3 to T4 is consistent with invasion of
prostate cancer cells extending beyond the prostatic capsule during this stage. Our results
also revealed upregulation of the gene expression of the small Cajal body-specific RNA
(scaRNA22) from stages T2c to T3/T4. scaRNA22 is a non-coding RNA involved in the
maturation of other RNA molecules, and along with other small nucleolar RNA, has been

Table 5.9: Top transcripts that discriminate stages T2C and T3/T4 of prostate cancer.
Transcript
NM 001257413

Chr.
17

Type
mRNA

NM 003940

3

mRNA

NM 001142274

2

mRNA

NM 001199165

17

mRNA

NM 052965

1

mRNA

NM 001195283

14

mRNA

NM 001023567

15

mRNA

NM 001143766

10

mRNA

NR 003004
NM 017753

4
9

snoRNA
mRNA

NM 000959

1

mRNA

NM 004772

5

mRNA

Description
IKAROS family zinc finger 3 (Aiolos) , transcript variant 12
Ubiquitin specific peptidase 13
(isopeptidase T-3)
Cytoplasmic linker associated protein 1, transcript
variant 3
Centrosomal protein 112kDa, transcript variant 3
tRNA splicing endonuclease subunit,
transcript variant 1
Feline leukemia virus subgroup C cellular receptor. family, member 2,
transcript variant 2
Golgin A8 family, member B, transcript variant 1
Zinc finger protein 438, transcript
variant 1
Small Cajal body-specific RNA 22
Lipid phosphate phosphatase-related
protein. type 1, transcript variant 2
Prostaglandin F receptor (FP), transcript variant 1
Neuronal regeneration related protein, transcript variant 1
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Gene
IKZF3
USP13
CLASP1

CEP112
TSEN15
FLVCR2

GOLGA8B
ZNF438
SCARNA22
LPPR1
PTGFR
NREP

linked to human cancers [25]. Typically located in the introns of host genes, upregulation
of scaRNA22 was found in multiple myeloma harboring chromosomal translocations and
may suppress oxidative stress, facilitate cell proliferation and protect cells from the effects
of chemotherapy [26]. Our study is the first to link scaRNA22 with prostate cancer and
progression of the disease.
In particular, we have isolated a set of transcripts that are significantly altered at the
critical transition between stages T2 and T3/4 and remain elevated. These are transcripts
from the genes DOCK9, FLVCR2, IK2F3, USP13, PTGFR and CLASP1. In the human
protein atlas, Dock9, Clasp1 and USP13 protein levels are highly expressed in prostate
cancer tissues. Dock9 is a Rho GEF responsible for activating Rho-GTPases and known to
be implicated in tumorigenesis [27, 28]. While the protein atlas has not detected PTGFR

Table 5.10: Comparison between CuffDiff and our feature-selection method for identifying differentially
expressed transcripts between each pair of consecutive stages of prostate cancer.
Stage

Method

T1C-T2
(14 vs 10)
T2-T2A
(10 vs 23)
T2A-T2B
(23 vs 11)
T2B-T2C
(11 vs 30)
T2C-T3A
(30 vs 8)
T3A-T3B
(8 vs 9)
T2CT3/T4
(30 vs 17)

CuffDiff

#
selected
Transcripts
21

# Common
Transcripts
0

ACC

FM

MCC

AUC

70.8%

0.710

0.410

0.846

Proposed Method
CuffDiff

6
43

0

95.8%
69.7%

0.958
0.650

0.917
0.159

0.971
0.580

Proposed Method
CuffDiff

7
35

0

93.9%
64.7%

0.939
0.601

0.857
0.068

0.970
0.634

Proposed Method
CuffDiff

6
38

0

85.3%
65.8%

0.851
0.647

0.657
0.078

0.826
0.645

Proposed Method
CuffDiff

5
29

0

87.8%
73.7%

0.880
0.722

0.699
0.130

0.885
0.612

Proposed Method
CuffDiff

5
27

0

89.4%
58.8%

0.895
0.588

0.683
0.181

0.948
0.750

Proposed Method
CuffDiff

3
49

0

94.1%
57.4%

0.941
0.568

0.887
0.055

1.000
0.483

Proposed Method

12

95.7%

0.957

0.908

0.988
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as highly stained in prostate cancer, gene expression of PTGFR is associated with cell
proliferation and in vivo progression to castration-recurrent prostate cancer, an end stage
of the disease [29]. In ovarian cancer, overexpression of PTGFR stimulates the spontaneous
development and secretion of autoantibodies against the protein, as detected in the sera
of cancer patients [30]. Autoantibodies against PTGFR may serve as biomarkers for early
serological detection of the disease. Overexpression of PTGFR has also been reported in
human tumor-endothelial cells of renal cell carcinoma where it is believed to be involved in
tumor angiogenesis [31]. Whether these transcripts, or their protein products, can be used
alone or in combination as a prognostic indicator for prostate cancer is an important next
step of this work. It is also interesting to consider that these protein products may represent
novel drug targets for advanced disease.

Figure 5.5: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T1c and T2.
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Figure 5.6: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T2 and T2a.
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Figure 5.7: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T2a and T2b.

Figure 5.8: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T2b and T2c.
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Figure 5.9: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T2c and T3a.

Figure 5.10: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T3a and T3b.
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Figure 5.11: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T2c and T3/T4.
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Chapter 6

Conclusion and future work
6.1

Conclusion

The main contribution of this thesis is to provide a generic pipeline for modeling RNASeq data as a supervised or non supervised learning scheme used to obtain meaningful
biomarkers in cancer. Starting from preprocessing RNA-Seq data to model the different
cancer problems, the proposed model showed high performance and throughput. Via this
model we were able to extract transcriptomic biomarkers that are strongly related to prostate
cancer, breast cancer and other types of cancers. Additionally, we have performed biological
validation using the literature and in collaboration with biologists to investigate the obtained
biomarkers using wet-lab experiments, such as what has been done for CAMK2G in Chapter
3. We were also able to identify some other biomarkers such as a novel transcripts for WW2
genes, while processing the data set from Chinese populations. Our biologist collaborators
deeply investigated WW2 and found that the novel transcript can double the gene expression
in the cancer cell lines [1].
The main methods of this work were able to handle different machine learning problems
such as the curse of dimensionality and narrowing down the number of biomarker genes to
a few of them, in order to furhter analyze them. We also solved the problem of data sets
with imbalanced classes (in which the standard classifiers are biased towards the majority
class) as in Chapter 4 models, and we were able to detect the harmful minor miRNA from
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Table 6.1: List of biomarkers that have been extracted by our methods
Biomarker
WWP2
STMN1
CAMK2G
RUNX3
MSMB
PLA2G2A
AGR2
TFF3
YBX1
CX3CL1
BUB1
COX4NB
PSAP
SCGB2A2

Transcriptomic type
novel transcript
transcript N M0 05563
transcript N M0 01222
transcript N M0 04350
transcript N M0 02443
transcript N M0 01161728
Gene expression
Gene expression
Gene expression
Gene expression
Gene expression
Gene expression
Gene expression
Gene expression

Cancer problem
prostate progression
prostate progression
prostate progression
prostate progression
prostate progression
prostate progression
Breast cancer subtype - Basel
Breast cancer subtype - Basel
Breast cancer subtype - Her2
Breast cancer subtype - Normal
Breast cancer subtype - LumA
Breast cancer subtype - LumB
Breast cancer time-series Outlier (survival-treatment)
Breast cancer time-series Outlier - oncogene

the majority of other non-coding RNA [2]. As an initial step of this work, we have tried
different machine learning models to cluster transcriptomic profiles in order to find patterns
from time-series data [3]. In this thesis, we did not only apply well-known machine learning
approaches to analyze RNA-Seq cancer data, but we also created our own methods to handle
different machine learning problems.
In a nutshell, the contributions in this work can be summarized as follows.
• Proposing a new method for preprocessing RNA-Seq data used to remove low-complex
and highly-biased sequences from sequence reads.
• Modeling the cancer development (growth) using real data that have been taken from
different patients with different Cancer stages.
• Creating genomic and transcriptomic profiles with read quantifications on different time
series points (cancer stages) by interpolating the development of the profiles using cubicspline.
• Devising a machine learning model based on hierarchal clustering for finding outliers
from time-series data.
• Handling the multi-class problem using the one-versus-next approach for prostate cancer
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stages, and the one-versus-rest approach for breast cancer survivability treatments and
breast cancer subtype analysis.
• Finding biomarkers from time-series profiles, which follow different trends different than
the majority of the transcripts (background).
• Enhancing the generic hierarchical clustering method to detect both global and local
outliers.
Most parts of this work have been published in conferences in collaborations with my lab
mates, who have jointly co-authored these publications. Chapter 2, Zseq the preprocessing
tool for RNA-Seq data, has been published as a journal article, while the rest is either being
under review or going to be extended as journal articles which are in preparation.

6.2

Future work

Although we have proposed and developed powerful approaches for dealing with RNA-Seq
data, finding meaningful biomarkers and modelling cancer, there is some room for improvement. The future work and extensions of this work are divided into two areas: biomarkers
and the underlying methods. For the biomarkers, we can further analyze, biologically, the
obtained biomarkers using different types of pathway analysis and wet-lab experiments that
are related to each cancer type or stage. For the hierarchical clustering method, we can further automate the PAAC index using multi-objective optimization methods, such as Pareto
optimization [4].
Another future avenue to this work is to create an integrative approach that reads from
different sources of data for a specific type of cancer such as gene expression, RNA-Seq, CNA,
CNV, mutations and build a deep learning model that can learn from those different sources
and analyze the causes, treatments, and survivability chances of cancer based on specific
treatments. The pipeline resulting from this work can be integrated with a tool which we have
already started work on to find protein isoforms in the transcriptomic profiles [5]. Once we
extract the protein isoforms from RNA-Seq data, we can target protein-protein interactions
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with drugs obtained from databases such as DrugBank [6] to study the most effective path of
treatment. The mutations in the RNA-Seq data can help us develop personalized medicine
approaches by checking whether a person mutation happens in a specific enzyme that may
effect the drug metabolism, which it may speed it up, slow it down, or shut down the whole
metabolism [7], which may lead to different responses from one patient to another due to
mutations or other genomic changes.
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Appendix A

Clustering time-series profiles using
wavelet based probability density
functions (PDF) for identifying
patterns in time series
A.1

The proposed clustering method

In this section, the proposed clustering method based on the combination of the probability
density function and hierarchical method is introduced. For this purpose, a wavelet based
probability density function is introduced to estimate a mixture of the PDF for each feature.
Then, “multi-level” thresholding is implemented to the PDF of the feature to cluster dataset.
After this stage, forward feature selection with memory is utilized to combine the features
and to maximize the number of the clusters. The PAAC index is considered for evaluating
the number of clusters and features.
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A.1.1

Wavelet-based density function estimation

The probability density function of each feature is estimated by wavelet basis function [1,2].
The orthogonal basis functions of the wavelets along with their localized properties provide
an accurate estimation of the PDF. In this method, a particular shape is not contended for
the PDF and let the data, itself, determine the shape of the PDF. For this purpose, suppose
that the data of feature x is available as (x(t), 1 ≤ t ≤ n), the density function of feature
x is unknown. The aim is to predict this density function, h(x), via the multi resolution
analysis introduced by Mallat [4]. For this aim, h(x) is considered as a linear combination
of scaling functions and its orthogonal wavelets as follows:

h (x) =

+∞
X

a0,k Φ0,k (x) +

+∞
X

dm,k Ψm,k (x)

(A.1)

m=−∞ k=−∞

k=−∞

Φm,k (x) = 2

0
X

−m
2

Ψm,k (x) = 2


Φ 2−m x − k , m, k ∈ Z

−m
2


2−m x − k , m, k ∈ Z

(A.2)
(A.3)

Where Φm,k (x) and Ψm,k (x) are scaling functions and their orthogonal wavelets, and m and,
k are dilation and translation factors of the scaling functions and the wavelets, respectively.
Furthermore, 2

−m
2

is used as an energy normalization factor. a0,k and dm,k are computed as

follows:

a0,k = h, Φ0,k > = ∫ Φ0,k (x) h (x) dx

(A.4)

dm,k = h, Ψm,k >= ∫ Ψm,k (x) h (x) dx

(A.5)

It must be noted that h(x) is not available, and a0,k and dm,k cannot be achieved by Eqs. (4)
and (5). Fortunately, h (x) is a density function, and hence ∫ Φ0,k (x) h (x) dxis equal to the
expectation of Φ0,k (x)and ∫ Ψm,k (x) h (x) dxis equal to the expectation of Ψm,k (x)Thus,
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a0,k and dm,k can be formulated as follows:
n

a0,k

1X
Φ0,k (x (t))
= ∫ Φ0,k (x) h (x) dx = E (Φ0,k (x)) =
n t=1

(A.6)

n

dm,k

1X
= ∫ Ψm,k (x) h (x) dx = E (Ψm,k (x)) =
Ψm,k (x (t))
n t=1

(A.7)

It should be noted that the PDF obtained by Eqs (1), (6) and (7) are not smooth. There are
many methods for smoothing of the suggested PDF in the literature such as soft-thresholding
and hard-thresholding [1, 2].
A.1.2

The multi-level thresholding method

This subsection briefly illustrates multi-level thresholding method for clustering each feature
based on its PDF. Optimal multi thresholding is an important task in pattern recognition.
Rueda introduces a polynomial-time method for multilevel thresholding of irregularly sampled histograms based on dynamic programming. The algorithm is polynomial not only
on the number of bins of the histogram, n, but also on the number of thresholds, k. The
algorithm can be generally applied for a wide range of thresholding and clustering criteria,
and it can be able to deal with irregularly sampled histograms. Furthermore, the algorithm
can determine the optimal thresholds in a fraction of a second. It should be noted that the

worst-case time complexity of the algorithm is θ kn2 [3].
A.1.3

Forward feature selection with memory

In this subsection, a forward feature selection (floating search method) is presented [5, 6] to
merge the features and to provide the maximum number of the clusters. The forward feature
section algorithm engages starting with no features in the model, then, it tests adding of
each feature using a model comparison criterion, adding the feature if the feature improves
the model criterion. The algorithm repeats the process until no improvement in the model.
However, the algorithm is greedy and it is not optimal. To improve the performance of the
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method, the algorithm is considered with a memory known as the floating search method.
In the floating search method, the algorithm keeps the best feature and the second best
feature (memory) at each step. Although, the algorithm is still greedy and not optimal, but
it improves the performance of the method and it can be suboptimal.
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Appendix B

The clinical and sequencing details of
the Chinese prostate cancer dataset
All the sequencing runs for the dataset samples shares the following features: ethnic group
= Chinese, sex = male, Organism = Homo sapiens, disease = prostate carcinoma, Organism
part = prostate gland, Protocol REF = P-MTAB-33294, Library source = Transcriptomic,
Direction = Forward, Library layout = paired, Library selection = cDNA, Orientation =
5’-3’-5’-3’, Nominal length = 200bp, Performer = BGI, Technology type = sequencing assay.
While they have the following different features as seen in Table B.1:
Table B.1: The details of the samples sequencing runs
for the Chinese dataset.
Source

Patient age

sampling

Extract

Assay

Name

id

site

Name

Name

ENA RUN

FactorValue
sampling
site

10N

10

75

adjacent

10N

10N 1

ERR031017

adjacent

non-tumor

non-tumor

tissue

tissue

139

10N

10T

10

10

75

75

adjacent

10N

10N 2

ERR031017

non-tumor

non-tumor

tissue

tissue

tumor tis-

10T

10T 1

ERR031018

sue
10T

10

75

tumor tis-

11N

11T

11

11

11

57

57

57

adjacent

10T

10T 2

ERR031018

11

57

11N

11N 1

ERR031019

12N

12T

12

12

12

80

80

80

non-tumor

tissue

tissue

adjacent

11N

11N 2

ERR031019

12

80

adjacent

non-tumor

non-tumor

tissue

tissue

tumor tis-

11T

11T 1

ERR299295

tumor tis-

adjacent

tumor tissue

11T

11T 2

ERR299295

tumor tissue

12N

12N 1

ERR299296

adjacent

non-tumor

non-tumor

tissue

tissue

adjacent

12N

12N 2

ERR299296

adjacent

non-tumor

non-tumor

tissue

tissue

tumor tis-

12T

12T 1

ERR031022

sue
12T

adjacent

non-tumor

sue
12N

tumor tissue

sue
11T

tumor tissue

sue
11N

adjacent

tumor tis-

tumor tissue

12T

sue

12T 2

ERR031022

tumor tissue

140

13N

13N

13T

13

13

13

75

75

75

adjacent

13N

13N 1

ERR031023

non-tumor

non-tumor

tissue

tissue

adjacent

13N

13N 2

ERR031023

13

75

non-tumor

tissue

tissue

tumor tis-

13T

13T 1

ERR031024

tumor tis-

14N

14T

14

14

14

73

73

73

adjacent

13T

13T 2

ERR031024

14

73

14N

14N 1

ERR031025

1N

1

1

74

74

adjacent

non-tumor

non-tumor

tissue

tissue

adjacent

14N

14N 2

ERR031025

adjacent

non-tumor

non-tumor

tissue

tissue

tumor tis-

14T

14T 1

ERR031026

tumor tis-

adjacent

tumor tissue

14T

14T 2

ERR031026

sue
1N

tumor tissue

sue
14T

tumor tissue

sue
14N

adjacent

non-tumor

sue
13T

adjacent

tumor tissue

1N

1N 1

ERR031027

adjacent

non-tumor

non-tumor

tissue

tissue

adjacent

1N

1N 2

ERR031027

adjacent

non-tumor

non-tumor

tissue

tissue

141

1T

1

74

tumor tis-

1T

1T 1

ERR031028

sue
1T

1

74

tumor tis-

sue
1T

1T 2

ERR031028

sue
2N

2N

2T

2

2

2

73

73

73

adjacent

2

73

2N

2N 1

ERR031029

3N

3T

3

3

3

71

71

71

non-tumor

tissue

tissue

adjacent

2N

2N 2

ERR031029

3

71

non-tumor

tissue

tissue

tumor tis-

2T

2T 1

ERR031030

tumor tis-

adjacent

4

54

tumor tissue

2T

2T 2

ERR031030

tumor tissue

3N

3N 1

ERR031031

adjacent

non-tumor

non-tumor

tissue

tissue

adjacent

3N

3N 2

ERR031031

adjacent

non-tumor

non-tumor

tissue

tissue

tumor tis-

3T

3T 1

ERR031032

tumor tis-

adjacent

tumor tissue

3T

3T 2

ERR031032

sue
4N

adjacent

non-tumor

sue
3T

adjacent

non-tumor

sue
3N

tumor tissue

sue
2T

tumor tis-

tumor tissue

4N

4N 1

ERR031033

adjacent

non-tumor

non-tumor

tissue

tissue
142

4N

4T

4

4

54

54

adjacent

4N

4N 2

ERR031033

non-tumor

non-tumor

tissue

tissue

tumor tis-

4T

4T 1

ERR299297

sue
4T

4

54

tumor tis-

5N

5T

5

5

5

62

62

62

adjacent

4T

4T 2

ERR299297

5

62

5N

5N 1

ERR031035

6N

6T

6

6

6

69

69

69

non-tumor

tissue

tissue

adjacent

5N

5N 2

ERR031035

6

69

adjacent

non-tumor

non-tumor

tissue

tissue

tumor tis-

5T

5T 1

ERR299298

tumor tis-

adjacent

tumor tissue

5T

5T 2

ERR299298

tumor tissue

6N

6N 1

ERR299299

adjacent

non-tumor

non-tumor

tissue

tissue

adjacent

6N

6N 2

ERR299299

adjacent

non-tumor

non-tumor

tissue

tissue

tumor tis-

6T

6T 1

ERR031038

sue
6T

adjacent

non-tumor

sue
6N

tumor tissue

sue
5T

tumor tissue

sue
5N

adjacent

tumor tis-

tumor tissue

6T

sue

6T 2

ERR031038

tumor tissue

143

7N

7N

7T

7

7

7

52

52

52

adjacent

7N

7N 1

ERR031039

non-tumor

non-tumor

tissue

tissue

adjacent

7N

7N 2

ERR031039

7

52

non-tumor

tissue

tissue

tumor tis-

7T

7T 1

ERR031040

tumor tis-

8N

8T

8

8

8

66

66

66

adjacent

7T

7T 2

ERR031040

8

66

8N

8N 1

ERR031041

9N

9

9

56

56

adjacent

non-tumor

non-tumor

tissue

tissue

adjacent

8N

8N 2

ERR031041

adjacent

non-tumor

non-tumor

tissue

tissue

tumor tis-

8T

8T 1

ERR031042

tumor tis-

adjacent

tumor tissue

8T

8T 2

ERR031042

sue
9N

tumor tissue

sue
8T

tumor tissue

sue
8N

adjacent

non-tumor

sue
7T

adjacent

tumor tissue

9N

9N 1

ERR031043

adjacent

non-tumor

non-tumor

tissue

tissue

adjacent

9N

9N 2

ERR031043

adjacent

non-tumor

non-tumor

tissue

tissue

144

9T

9

56

tumor tis-

9T

9T 1

ERR031044

sue
9T

9

56

tumor tis-

tumor tissue

9T

sue

9T 2

ERR031044

tumor tissue
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Appendix C

The clinical and sequencing details of
the North American prostate cancer
dataset
Table C.1:

The clinical and sequencing information of

the samples from the North American dataset.

CGSR ID

External

Study

no.

of

%

Gleason age race pStage

ID

ID

uniquely

mapped Score

mapped

reads

reads
PT081

PT127

PT168

MCC-

MCC-

PT081

PT081

MCC-

MCC-

PT127

PT127

MCC-

MCC-

PT168

PT168

251,516,583 63.0%

347

78.0 W

pT3

9,995,053

65.8%

336

61.0 W

pT2

10,476,268 64.6%

336

63.0 W

pT2

146

PT184

20,241,959 67.0%

347

58.0 NA

pT3

13,030,802 64.4%

347

57.0 W

pT2

15,108,250 66.2%

347

54.0 W

pT2

20,783,424 62.1%

347

43.0 NA

pT2

UTPC008

UTPC008 UTPC008 101,038,395 69.0%

437

57.0 NA

pT1C

UTPC020

UTPC020 UTPC020 48,519,295 56.9%

448

66.0 NA

pT2B

UTPC107

UTPC107 UTPC107 60,698,177 62.7%

336

50.0 NA

pT1C

CM.1-

UTPC162 UTPC162 16,673,391 63.8%

347

69.0 NA

pT1C

VA-PC-

PT199

PT236

PT243

MCC-

MCC-

PT184

PT184

MCC-

MCC-

PT199

PT199

MCC-

MCC-

PT236

PT236

MCC-

MCC-

PT243

PT243

0028.1
CM.4-0087

00LH1

58,978,596 72.9%

347

68.8 B

pT2C

00JC1

26,387,543 46.5%

347

55.6 B

pT2

00AS1

29,052,523 66.4%

437

62.1 W

pT2C

00ES1

53,860,194 70.5%

538

63.1 B

pT3A

00CH1

95,708,411 80.0%

347

52.5 W

pT2A

00JB1

49,844,364 69.1%

347

62.4 B

pT3A

00HA1

59,522,602 66.1%

347

69.0 B

pT2C

00-87
CM.4-0090

VA-PC00-90

CM.4-0091

VA-PC00-91

CM.4-0092

VA-PC00-92

CM.4-0093

VA-PC00-93

CM.4-0094

VA-PC00-94

CM.4-0095

VA-PC00-95

147

CM.4-0097

VA-PC-

00JJ2

81,114,085 77.0%

336

51.4 W

pT2C

00JM1

30,149,534 72.0%

347

68.4 W

pT2C

91HH1

39,377,172 49.7%

437

56.6 W

pT2C

91EM1

58,589,794 62.9%

448

63.8 W

pT2C

91HL1

50,897,494 79.9%

347

69.1 W

pT2C

92GG1

9,199,337

68.4%

347

64.9 W

pT2A

92WM1

58,111,320 46.9%

347

70.2 W

pT2C

92LS1

42,010,928 47.7%

347

65.1 W

pT2

92PG1

42,716,254 60.1%

347

66.6 W

pT2

93RS1

21,723,177 80.1%

347

64.1 W

pT2A

93CA1

50,028,024 70.6%

437

61.3 W

pT2C

94CD1

82,057,308 69.9%

347

56.3 B

pT2C

94JL1

66,648,540 72.5%

347

69.6 B

pT3A

00-97
CM.4-0098

VA-PC00-98

CM.4-0061

VA-PC91-61

CM.4-0062

VA-PC91-62

CM.4-0064

VA-PC91-64

CM.4-0013

VA-PC92-13

CM.4-0014

VA-PC92-14

CM.4-0066

VA-PC92-66

CM.4-0067

VA-PC92-67

CM.4-0019

VA-PC93-19

CM.4-0068

VA-PC93-68

CM.4-0028

VA-PC94-28

CM.4-0070

VA-PC94-70

148

CM.4-0045

VA-PC-

96HH1

39,787,464 64.1%

347

50.4 W

pT3A

97RM1

16,010,891 19.6%

347

53.7 W

pT2C

97EC1

39,114,735 59.9%

347

50.0 B

pT2C

97WT1

38,014,897 45.3%

336

64.2 W

pT2A

97JS1

42,286,269 47.8%

347

60.5 W

pT2A

97FH1

21,954,686 29.3%

437

57.3 B

pT2B

97DS1

14,877,664 14.9%

437

64.0 W

pT2C

97RS1

96,287,979 66.6%

347

72.4 W

pT2C

99RE1

49,857,683 69.8%

437

59.0 W

pT2A

99BE1

47,695,326 51.2%

347

47.2 B

pT2C

99WW1

91,549,024 48.7%

347

54.4 W

pT2A

99TD1

45,313,892 55.0%

347

54.7 W

pT2C

99AS1

32,490,259 75.1%

336

55.9 B

pT2A

96-45
CM.4-0047

VA-PC97-47

CM.4-0048

VA-PC97-48

CM.4-0049

VA-PC97-49

CM.4-0050

VA-PC97-50

CM.4-0051

VA-PC97-51

CM.4-0052

VA-PC97-52

CM.4-0074

VA-PC97-74

CM.4-0054

VA-PC99-54

CM.4-0055

VA-PC99-55

CM.4-0075

VA-PC99-75

CM.4-0076

VA-PC99-76

CM.4-0077

VA-PC99-77

149

CM.4-0078

VA-PC-

99DH1

64,869,418 75.3%

347

62.4 B

pT2A

99CT1

31,069,486 78.4%

347

64.8 W

pT2B

99LH1

82,407,763 60.0%

347

54.4 B

pT2C

99LW1

32,471,983 70.7%

437

65.6 W

pT2

99CC1

65,045,734 55.0%

347

62.5 W

pT2C

99WM1

52,536,474 62.6%

347

50.4 B

pT2A

99RR1

24,586,944 59.1%

336

64.7 W

pT2A

83,866,689 60.9%

336

66.0 W

pT1C

72,366,520 43.2%

336

61.3 W

pT1C

71,163,980 54.0%

325

60.1 W

NA

73,667,210 58.9%

549

71.0 NA

pT1C

UTPC004

UTPC004 UTPC004 94,148,591 61.6%

549

71.0 NA

pT1C

CM.1-

UTPC009 UTPC9

16,891,119 56.4%

347

50.0 NA

pT2B

UTPC009 UTPC009 95,747,467 57.4%

347

50.0 NA

pT2B

99-78
CM.4-0079

VA-PC99-79

CM.4-0080

VA-PC99-80

CM.4-0081

VA-PC99-81

CM.4-0082

VA-PC99-82

CM.4-0083

VA-PC99-83

CM.4-0084

VA-PC99-84

PT197

MCCPT197

PT220

MCCPT220

PT264

MCCPT264

CM.1-

UTPC004 UTPC4

0001.1

0002.1
UTPC009

150

CM.1-

UTPC019 UTPC19 59,982,964 54.8%

437

64.0 NA

pT2A

UTPC019

UTPC019 UTPC019 52,303,635 55.1%

437

64.0 NA

pT2A

CM.1-

UTPC021 UTPC21 46,997,412 39.9%

437

68.0 NA

pT1C

UTPC021

UTPC021 UTPC021 46,997,412 52.8%

437

68.0 NA

pT1C

CM.1-

UTPC029 UTPC29 65,468,819 57.2%

347

58.0 W

pT2A

UTPC029

UTPC029 UTPC029 100,596,892 58.4%

347

58.0 NA

pT2A

CM.1-

UTPC034 UTPC34 18,135,372 41.3%

347

55.0 NA

pT2B

UTPC034

UTPC034 UTPC034 111,754,397 62.1%

347

55.0 NA

pT2B

UTPC041

UTPC041 UTPC041 95,370,297 63.5%

347

71.0 NA

pT1C

CM.1-

UTPC058 UTPC58 17,542,055 43.6%

347

65.0 NA

pT2B

UTPC088 UTPC88 25,814,843 60.8%

336

62.0 NA

pT1C

UTPC093 UTPC93 16,692,025 56.9%

347

58.0 NA

pT2A

UTPC099 UTPC99 13,757,579 55.5%

459

67.0 NA

pT2B

UTPC101 UTPC101 75,959,530 55.1%

448

70.0 NA

pT3B

UTPC104 UTPC104 75,764,019 58.9%

437

59.0 NA

pT2A

UTPC110 UTPC110 25,416,364 67.2%

549

53.0 NA

pT2B

0003.1

0004.1

0005.1

0006.1

0008.1
CM.10012.1
CM.10013.1
CM.10015.1
CM.10016.1
CM.10017.1
CM.10018.1
151

CM.1-

UTPC114 UTPC114 64,266,720 63.6%

347

60.0 NA

pT1C

UTPC116 UTPC116 20,810,790 69.1%

347

60.0 NA

pT2A

UTPC127 UTPC127 86,871,782 63.9%

437

58.0 NA

pT3B

UTPC131 UTPC131 18,275,411 64.4%

437

51.0 NA

pT3B

UTPC132 UTPC132 31,782,258 47.8%

437

65.0 NA

pT2A

UTPC141 UTPC141 57,654,792 48.8%

347

74.0 NA

pT2A

UTPC146 UTPC146 34,232,839 49.8%

448

72.0 W

pT3B

UTPC147 UTPC147 17,789,548 60.1%

347

66.0 NA

pT2A

UTPC160

UTPC160 UTPC160 32,943,917 28.2%

347

57.0 NA

pT1C

UTPC164

UTPC164 UTPC164 123,211,885 61.2%

437

66.0 NA

pT2A

CM.1-

UTPC170 UTPC170 70,019,189 66.0%

437

72.0 NA

pT1C

VA-PC-

0019.1
CM.10020.1
CM.10021.1
CM.10022.1
CM.10023.1
CM.10025.1
CM.10026.1
CM.10027.1

0030.1
CM.4-0086

00TW1

100,294,010 77.2%

437

59.6 B

pT3B

00JS1

94,922,445 68.3%

347

53.5 B

pT2C

00DF1

102,465,236 65.8%

437

58.4 W

pT2C

00-86
CM.4-0088

VA-PC00-88

CM.4-0096

VA-PC00-96

152

CM.4-0099

VA-PC-

00AR1

67,659,170 74.6%

437

65.7 B

pT3A

90GD1

79,371,670 63.0%

448

59.0 NA

pT3B

91JP1

62,526,982 72.7%

459

55.0 B

pT3B

92AC1

91,714,533 61.8%

448

63.9 W

pT3B

92HM1

37,147,471 47.6%

347

67.4 W

pT3B

93JM1

74,903,758 75.2%

448

52.0 W

pT2C

93AS1

73,477,400 65.3%

347

66.5 W

pT2C

93FC1

34,139,269 44.8%

437

66.6 W

pT2

94JH1

59,808,026 74.4%

448

64.8 W

pT2C

95CM1

30,409,790 48.5%

347

62.0 W

pT2C

95BB1

50,090,466 62.3%

347

57.7 B

pT2C

95HD1

48,679,745 56.3%

347

58.0 B

pT2C

95CJ1

23,750,742 51.0%

347

66.8 W

pT4

00-99
CM.4-0004

VA-PC90-4

CM.4-0065

VA-PC91-65

CM.4-0011

VA-PC92-11

CM.4-0009

VA-PC92-9

CM.4-0020

VA-PC93-20

CM.4-0021

VA-PC93-21

CM.4-0024

VA-PC93-24

CM.4-0071

VA-PC94-71

CM.4-0034

VA-PC95-34

CM.4-0037

VA-PC95-37

CM.4-0041

VA-PC95-41

CM.4-0042

VA-PC95-42

153

CM.4-0043

VA-PC-

96JL1

84,811,432 61.1%

437

61.8 W

pT2C

96DC1

70,792,590 62.0%

347

51.8 B

pT2C

97RC1

71,695,143 58.8%

437

58.6 W

pT2C

98RS2

85,477,421 66.9%

448

61.6 B

pT2A

99JH1

96,977,746 81.4%

347

56.9 W

pT3A

96-43
CM.4-0044

VA-PC96-44

CM.4-0046

VA-PC97-46

CM.4-0053

VA-PC98-53

CM.4-0085

VA-PC99-85
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